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Abstract 
Celiac Disease (CD) is a chronic enterophaty affecting the small intestine 
and triggered by gluten proteins contained in wheat, barley and rye. It is 
characterized by an autoimmune response in genetically susceptible 
individuals, and only the 40% of the genetics is explained by HLA 
predisposition. Recently, several susceptibility loci not HLA related have 
been identified by genome-wide association studies (GWAs). Our aim is to 
extract as many information as we can from the large amount of data 
emerged from these studies.  
Firstly, we tried to improve the analyses of candidate genes characterizing 
their expression profile and comparing the results obtained on mucosal 
biopsies, peripheral monocytes and T-cell lines isolated from duodenal 
mucosa, in order to better understand the variation in the celiac type and 
to correlate it with a model of CD pathogenesis. Furthermore we 
investigated the non-HLA genetics of Potential CD patients and this 
allowed us to speculate that these patients are a mixture of two 
populations, with different non-HLA genetics. We also used the new 
genetic findings to build a risk model for CD using HLA and non-HLA risk 
alleles. In both these two last cases we aimed to significantly improve the 
identification of subjects at risk to develop CD.  
The critic analysis of the large panorama of CD candidate genes leads to 
consider several mechanisms of action that may have gone unnoticed if we 
persist in considering all the genes together. Whereas, analyzing a small 
set of genes from different points of view it is possible to really understand 
why this more than the other gene resulted to be associated with the 
disease. GWAs made the history of complex diseases, but represent only 
the starting point from which postulate hypothesis, mechanisms of action, 
interactions, in order to untangle the skein represented by the complex 
pathogenesis of celiac disease. 
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Introduction 
Celiac Disease 
Celiac Disease (CD) is a chronic, small-intestinal enteropathy, which is 
triggered by gluten proteins contained in wheat, barley and rye. CD is 
characterized by an autoimmune response in genetically susceptible 
individuals resulting in small-intestinal mucosal injury. As a consequence, 
malabsorption develops, which in turn results in malnutrition-related 
problems including anemia, vitamin deficiencies, osteoporosis, and 
neurological disorders. A gluten-free diet (GFD) is sufficient to treat the 
overwhelming majority of patients with CD. The currently estimated 
prevalence is 1%, with a statistical range of probability of 0.5–1.26% in the 
general population in Europe and the USA (Dubé et al., 2005). Even taking 
into account that the actual occurrence rate of CD has been 
underestimated for many decades, the prevalence of this disease is 
increasing. 
The spectrum of clinical manifestations is wide, most of them are 
secondary to malabsorption, as well as the natural history is variable. This 
prompted the Associazione Italiana Celiachia (AIC) to classify the disease, 
distinguishing four different clinical forms:  
 Typical, early-onset (6-24 months) in a predominantly intestinal 
symptoms; 
 Atypical, late-onset (6-7 years) and mostly extra-intestinal 
symptoms; 
 Silent, which is CD without major digestive symptoms and so 
occasionally diagnosed in patients in apparent good health; 
 Potential, characterized by a positive serological markers, but 
with normal histology. 
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Several environmental, genetic and socioeconomic factors contribute to 
the development of CD.  
o Infant feeding: The role of infant feeding on the 
development of CD has been intensely debated since the 
late 1980s, which has resulted in a recommendation by 
the European Society for Pediatrics Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) committee. This 
committee currently recommends that small amounts of 
gluten have to be gradually introduced between 4 and 7 
months of age during breastfeeding (Agostoni et al., 
2008). 
o Infections: Infections after birth have been proposed to 
contribute to the development of CD. Whereas the role of 
infection with adenovirus type 12 in this process remains 
controversial, the association of Hepatitis C Virus infection 
and CD is well documented (Plot et al., 2009). 
o Socioeconomic features: An epidemiological survey where 
comparisons were made between schoolchildren living in 
a prosperous area of Finland and children living in an 
adjacent poor region of Russia, whom in part shared 
genetic susceptibility and gluten intake, has suggested 
that worse socioeconomic conditions might protect 
against CD development (Kondrashova et al., 2008). 
 
Diagnosis  
At present the most sensitive and specific serological tests for diagnosis 
of CD are assessments of the presence of IgA auto-antibodies against the 
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endomysium of connective tissue (EMA) and against tissue 
transglutaminase (tTG) (Rostami et al., 1999). 
In general, in case of strong clinical suspicion of CD, duodenal biopsy 
must be performed regardless of serological analysis; in cases of low 
suspicion of disease or screening, duodenal biopsy only needs to be 
performed in seropositive patients. 
Although HLA-DQ2 and/or HLA-DQ8 positivity is not an absolute 
requirement for diagnosis, as 40% of the healthy western population also 
carry genotypes for these molecules, CD is highly unlikely in case both of 
them are absent. As a consequence of this high negative predictive value 
for developing CD, HLA genotyping was proposed as a contributing 
element to diagnosis, in particular in the absence of villous atrophy 
(Kaukinen et al, 2002). 
 
Genetic risk factors 
A strong genetic component is suggested by: 
 Familial aggregation, as the prevalence of CD is 10 times 
higher in first degree familiars (~10%) than in the whole 
population (1%) (Bevan et al., 1999; Petronzelli et al., 1997); 
 Disease concordance in monozygotic twins (> 80%) than 
dizygotic (~10%) (Greco et al., 2002). 
HLA genes 
HLA alone can explain about ~40% of the genetic predisposition to 
disease (Bevan et al., 1999). The genetic risk factors are the genotypes 
encoding the HLA class II molecules HLA-DQ2 (encoded by HLA-
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DQA1*0501 and HLA-DQB1*02) and HLA-DQ8 (encoded by HLA-
DQA1*0301 and HLA-DQB1*0302). About 90% of individuals with CD carry 
the DQ2 heterodimer encoded either in cis or in trans, and almost all of 
the remaining patients express DQ8 (Sollid et al., 1989) (Figure 1). 
 
Figure 1. DQ2.5 haplotype is created by close genetic linkage of two alleles, written 
as a haplotype, DQA1*0501:DQB1*0201. The haplotype encodes DQ2.5cis isoform, 
referring to the cis arrangement of the DQA1*0501 and DQB1*0201 on the same variant 
of chromosome 6. The isoform can also be encoded trans-haplotype (between two sister 
chromosomes) forming the DQ2.5trans isoform. The DQ2.5 haplotype is linked to DR3. 
DQ2.2 is encoded almost exclusively by the DQA1*0201:DQB1*0202 haplotype. The 
haplotype is linked to DR7. DQA1*0301:DQB1*0302 (DQ8.1) is the most common DQ8 
subtype representing over 98% of the DQ-8 bearing population. 
 
Class II HLA molecules are localized on Antigen Presenting Cells (APC) 
surface and they are delegate to interact with T cell Receptor (TCR) in 
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order to present peptide molecules previously internalized by endocytosis, 
processed and brought to the surface. The molecules encoded by the 
genes of class II heterodimers are characterized by two transmembrane 
chains (α and β), and both chains are encoded by highly polymorphic 
genes (DQA and DQB, respectively) located in 6p chromosomal region. 
Most of the amino acid changes are located in a binding pocket which 
interacts with the antigenic peptide. The HLA polymorphism, therefore, 
affects the repertoire of peptides that can be presented to T lymphocytes 
and modulates immune response of each individual. 
Human Tissue Transglutaminase (TGase) has a very important role in 
promoting intestinal damage: it is present at the basal membrane of 
intestinal epithelial cells and can deamidate gliadin peptides which have a 
higher binding affinity to HLA-DQ2 and HLA-DQ8 molecules than native 
ones. Deamidation produces glutamic acid, rich in negative charges, from 
the neutral original Glutamine; since the DQ2 molecule preferentially 
accommodates in its binding site peptides leading negative residuals in 
their structure, deamidated gliadin peptides can cause a strongest 
response by binding with higher affinity to the HLA-DQ2 molecule (van de 
Wal et al., 1998).  
Non-HLA genes 
As it has been said previously, CD has a strong genetic component, 
more than others complex disease, and HLA genetic predisposition can 
explain only ~40% of the susceptibility to the disease. Currently, several 
susceptibility loci not related to HLA have been identified by genome-wide 
association studies (GWAs); these studies aimed to analyze two distinct 
populations of subjects: one (cases) characterized by presence of the 
disease, the other (controls) characterized by its absence. The hypothesis 
that supports an association study is that the presence of specific 
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polymorphisms in a locus (in particular Single Nucleotides Polymorphisms, 
SNPs) increases or decreases the risk to develop a complex diseases. There 
are in fact allelic variants that have a predisposing role to disease because 
they are more frequent in the population of affected individuals than in 
healthy controls, on the contrary there are variants with protective role 
that is less frequent in cases compared with healthy patients. 
The first GWAs showed that the 4q27 region, which harbors the IL2, 
IL21 and KIAA1109 genes, had the strongest association with CD after the 
HLA region (van Heel et al., 2007). The 4q27 region was immediately 
investigated also in other auto-immune disease and an association was 
found also with type I Diabetes (Todd et al., 2007), Psoriasis (Liu et al., 
2008) and Rheumatoid Arthritis (Zhernakova et al., 2007).  
In 2008 the same group performed a new GWAs on a case-controls 
cohort confirming the association of the 4q27 region and finding other 
seven regions in which there are nine candidate SNPs (Hunt et al., 2008). 
According to them, all the new 8 loci could explain ~3-4% of the 60% 
unexplained by HLA.  
From this point onwards, many replication on different population were 
performed in Europe, confirming or not for each SNP the association 
previously reported (Amundsen et al., 2010; Dema et al., 2009; Koskinen et 
al., 2009; J Romanos et al., 2009).  
In 2009 others two SNPs were supposed to be associated to CD (Trynka 
et al., 2009); both are localized in or in proximity of two genes encoding 
two proteins (c-REL and TNFAIP3) involved in NF-kB pathway, important 
inflammation mediators.  
With the last GWAs 13 risk variants were confirmed to be associated 
with CD, 13 new risk variants are proposed to be associated and further 13 
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met ‘suggestive’ criteria for association because of a little less significant p-
value: 39 risk variants in total (Dubois et al., 2010; Table 1).  
Chromosome Position SNP Gene of interest 
Previously reported risk variants 
1 190803436 rs2816316 RGS1 
2   61040333 rs13003464 REL, AHSA2 
2  102437000 rs917997 IL18RAP, IL18R1, IL1RL1, IL1RL2 
2  181704290 rs13010713 ITGA4, UBE2E3 
2  204510823 rs4675374 CTLA4, ICOS, CD28 
3  46210205 rs13098911 CCR1, CCR2, CCRL2, CCR3, CCR5, CCR9 
3  161147744 rs17810546 IL12A  
3  189595248 rs1464510 LPP 
4 123334952 rs13151961 IL2, IL21 
6 32713862 rs2187668 HLA-DQA1, HLA-DQB1 
6 138014761 rs2327832 TNFAIP3 
6 159385965 rs1738074 TAGAP 
12 110492139 rs653178 SH2B3 
18 12799340 rs1893217 PTPN2 
New loci, genome-wide significant evidence 
1  2516606 rs3748816 TNFRSF14, MMEL1 
1 25176163 rs10903122 RUNX3 
1 199158760 rs296547 ? 
2 68452459 rs17035378 PLEK 
3 32990473 rs13314993 CCR4 
3 120601486 rs11712165 CD80, KTELC1 
6 90983333 rs10806425 BACH2, MAP3K7 
6  128320491 rs802734 PTPRK, THEMIS 
8 129333771 rs9792269 ? 
10 80728033 rs1250552 ZMIZ1 
11 127886184 rs11221332 ETS1 
16 11311394 rs12928822 CIITA, SOCS1, CLEC16A 
21 44471849 rs4819388 ICOSLG 
New loci, suggestive evidence 
1  7969259 rs12727642 PARK7, TNFRSF9 
1 61564451 rs6691768 NFIA 
1 165678008 rs864537 CD24 
1 170977623 rs859637 FASLG, TNFSF18, TNFSF4 
3 69335589 rs6806528 FRMD4B 
3 170974795 rs10936599 ? 
6  328546 rs1033180 IRF4  
7 37341035 rs6974491 ELMO1 
13 49733716 rs2762051 ? 
14 68347957 rs4899260 ZFP36L1 
17  42220599 rs2074404 ? 
22 20312892 rs2298428 UBE2L3, YDJC 
X 12881445 rs5979785 TLR7, TLR8 
Table 1: Genomic regions with the strongest association signals for celiac disease 
(Dubois et al., 2010) 
The previous 13, the new 13 and the 13 new suggestive risk variants 
define the whole inflammation and immunological pathways, as shown by 
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the  DAVID results for Biological Process (http://david.abcc.ncifcrf.gov/; Table 
2). Candidate genes were grouped for Gene Ontology (GO) category and 
False Discovery Rate (FDR) has been fixed at<0.05. In a list of statistically 
significant findings (i.e. studies where the null-hypothesis could be 
rejected), FDR procedures are designed to control the expected proportion 
of incorrectly rejected null hypotheses ("false discoveries") (Benjamini & 
Hochberg, 1995). 
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Term Count P-value Genes FDR 
GO:0006955~immune response 
24 
(43.6%) 
3.64E-17 
HLA-DQB1, CIITA, IL18RAP, TNFSF4, THEMIS, CCR1, CTLA4, 
FASLG, TNFRSF14, TLR7, TNFSF18, TLR8, HLA-DQA1, CCR9, 
RGS1, CCR5, CCR4, ETS1, ICOS, CCR2, IL12A, ICOSLG, CD28, 
IL2 
5.63E-14 
GO:0050863~regulation of T cell activation 
10 
(18.2%) 
3.69E-10 
MAP3K7, CD80, IL12A, CTLA4, TNFRSF14, IRF4, IL21, 
ICOSLG, CD28, IL2 
5.71E-07 
GO:0050865~regulation of cell activation 
11 
(20.0%) 
6.66E-10 
MAP3K7, PLEK, CD80, IL12A, CTLA4, TNFRSF14, IRF4, IL21, 
ICOSLG, CD28, IL2 
1.03E-06 
GO:0042129~regulation of T cell proliferation 
8 
(14.5%) 
2.57E-09 CD80, IL12A, CTLA4, TNFRSF14, IL21, ICOSLG, CD28, IL2 3.97E-06 
GO:0051249~regulation of lymphocyte activation 
10 
(18.2%) 
3.01E-09 
MAP3K7, CD80, IL12A, CTLA4, TNFRSF14, IRF4, IL21, 
ICOSLG, CD28, IL2 
4.65E-06 
GO:0002694~regulation of leukocyte activation 
10 
(18.2%) 
8.26E-09 
MAP3K7, CD80, IL12A, CTLA4, TNFRSF14, IRF4, IL21, 
ICOSLG, CD28, IL2 
1.28E-05 
GO:0002684~positive regulation of immune system process 
11 
(20.0%) 
1.30E-08 
MAP3K7, CD80, THEMIS, CD247, IL12A, IL21, TLR7, TLR8, 
ICOSLG, CD28, IL2 
2.02E-05 
GO:0001817~regulation of cytokine production 
10 
(18.2%) 
1.76E-08 
MAP3K7, TNFSF4, CD80, REL, IL12A, IRF4, IL21, TLR7, TLR8, 
CD28 
2.72E-05 
GO:0042108~positive regulation of cytokine biosynthetic process 
7 
(12.7%) 
2.04E-08 CD80, REL, IRF4, IL21, TLR7, TLR8, CD28 3.15E-05 
GO:0050670~regulation of lymphocyte proliferation 
8 
(14.5%) 
2.04E-08 CD80, IL12A, CTLA4, TNFRSF14, IL21, ICOSLG, CD28, IL2 3.16E-05 
GO:0070663~regulation of leukocyte proliferation 
8 
(14.5%) 
2.22E-08 CD80, IL12A, CTLA4, TNFRSF14, IL21, ICOSLG, CD28, IL2 3.44E-05 
GO:0032944~regulation of mononuclear cell proliferation 
8 
(14.5%) 
2.22E-08 CD80, IL12A, CTLA4, TNFRSF14, IL21, ICOSLG, CD28, IL2 3.44E-05 
GO:0050867~positive regulation of cell activation 
8 
(14.5%) 
1.55E-07 MAP3K7, PLEK, CD80, IL12A, IL21, ICOSLG, CD28, IL2 2.39E-04 
GO:0042035~regulation of cytokine biosynthetic process 
7 
(12.7%) 
2.86E-07 CD80, REL, IRF4, IL21, TLR7, TLR8, CD28 4.43E-04 
GO:0042102~positive regulation of T cell proliferation 
6 
(10.9%) 
2.94E-07 CD80, IL12A, IL21, ICOSLG, CD28, IL2 4.55E-04 
GO:0050870~positive regulation of T cell activation 
7 
(12.7%) 
3.36E-07 MAP3K7, CD80, IL12A, IL21, ICOSLG, CD28, IL2 5.19E-04 
Table 2: DAVID results of associated genes located in 39 risk loci: Gene Ontology for Biological Processes. GO (Gene Ontology) is the number 
concatenated to category name (es. GO:0006955 is the category related to the immune response); (FDR) False discovery rate control is a statistical 
method used in multiple hypothesis testing to correct for multiple comparisons.  
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To simplify, the candidate genes were included in four categories:  
1. T-cell development in the thymus: the associated variants might 
alter biological processes before thymic MHC-ligand interactions. 
- THEMIS has a key regulatory role in both positive and negative 
T-cell selection during late thymocyte development.  
- RUNX3, a master regulator of CD8+ T lymphocyte 
development in the thymus.  
- TNFRSF14 has widespread functions in peripheral leukocytes 
and a crucial role in promoting thymocyte apoptosis. 
- The ETS1 transcription factor is also active in peripheral 
leukocytes; however, it is also a key player in thymic CD8+ 
lineage differentiation, acting in part by promoting RUNX3 
expression. 
 
2. Innate immune detection of viral RNA.  
- TLR7-TLR8 recognize viral RNA and viral infection (and the 
nature of the host response to infection) as a putative 
environmental trigger that could be common to these 
autoimmune diseases.  
 
3. T- and B-cell co-stimulation (or co-inhibition).  
- The association of genes like CTLA4- ICOS-CD28, TNFRSF14, 
CD80, ICOSLG, TNFRSF9, TNFSF4 indicate that fine control of 
the adaptive immune response might be altered in individuals 
at risk of CD.  
 
4. Cytokines, chemokines and their receptors. 
These confirmed susceptibility loci can explain approximately 20% of 
disease variance (Dubois et al., 2010) and help refine the pathways 
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involved in CD pathogenesis. Recently a new method using polygenic risk-
score analyses to infer the total liability-scale variance explained by 
associated GWAS SNPs was used to refine this value, and for CD the value 
obtained was 43% (excluding MHC contribute) (Stahl et al., 2012). 
Nonetheless, much more work needs to be done to explain the missing 
heritability and to understand the functional consequences of these risk 
alleles. 
 As it’s almost impossible to study all of them in a thorough way, we 
decided to focalize our attention on a few, in particular those which 
resulted to be associated with CD in different association studies on 
different populations and so less amenable to an environmental effect.  
 
Function of selected candidate genes 
Firstly we pointed attention on the 4q27 locus, because of its redundant 
positive result in all GWAs performed until now. Three main genes belong 
to this locus: KIAA1109, IL-2 and IL-21.   
Recent studies showed that the encoded protein of KIAA1109 gene 
(RefSeq Accession NP_056127.2) is similar to a Chinese hamster protein 
associated with spermatocyte and adipocyte differentiation (Wei et al., 
2006). The C-terminus of the protein is also similar to a Caenorhabditis 
elegans protein that plays a role in lipid storage (Wei et al., 2006). In 
mammals, this protein is thought to have a role in the regulation of 
epithelial growth and differentiation, and in tumor development (Kuo et 
al., 2006). The literature about KIAA1109 is very scarce, so it’s not well 
known how it could correlate with CD, even if this gene belongs to the 
4q27 locus which is the first and most associated one, after HLA, not only 
to CD (van Heel et al., 2007) but also to type I diabetes (Todd et al., 2007), 
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Psoriasis (Liu et al., 2008) and Rheumatoid Arthritis (Zhernakova et al., 
2007). 
IL-2 is produced from T cell after antigenic or mitotic stimulation and it 
works in autocrine or paracrine manner on monocytes and on T, B, LAK, NK 
and glioma cells. The decreased expression of IL-2 is associated to an 
organ-specific autoimmune reaction, because of its capacity to activate 
Treg cell (CD4+ CD25+) and so inhibiting the negative selection of T cell 
clones reactive towards self (Yamanouchi et al., 2007).  
IL-21 is one of the crucial cytokine in the inflammatory and gluten 
induced immune response. Its pro-inflammatory action directly correlates 
with the increase of IFN-γ (Fina et al., 2008). Moreover, together with IL-15 
promotes NK cell proliferation and maturation, and itself alone has the 
same effect on T and B cell as an answer to activating stimuli (De Nitto et 
al., 2009).  
c-REL is a subunit of the NF-B complex, and it is crucial for the 
regulation of this major nuclear factor which regulates the innate and 
adaptive immunity (Bonizzi et al., 2004). It’s regulation can terminate the 
NF-B activation by innate immune stimuli. The integral structure of c-REL 
is crucial for the activation as well as for the termination of NF-B induced 
immunoresponse (Lawrence et al., 2005). Our group produced evidences 
that NF-B is also constitutively active in intestinal mucosa of patients with 
untreated CD and reverts to normal values when gluten is removed from 
the diet (Maiuri et al., 2003).  
LPP (Lipoma Preferred Partner) gene encodes for a protein not directly 
implicated in immune and/or inflammatory disorders but according to 
recent GWAs the SNP association value is one of the highest, and so it 
seems to be more closely involved in the pathogenesis of CD than the 
others (Dubois et al., 2010); moreover this is the most associated gene also 
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in a family study, as reported by us (Izzo et al., 2011). It is a member of LIM 
domain-proteins family (Petit et al., 1996) probably involved in the 
regulation of shape, in cell polarity and motility (Petit et al., 2000), and in 
zinc finger protein transfer through cell-cell adhesions (Petit et al., 2003).  
RGS1 (Regulator of G-protein signaling 1) gene encodes a member of 
the “G protein signaling regulator” family which is probably involved in 
homing mechanism, because Rgs1-/- mice showed an increased B cell 
movement from and towards lymph nodes (Han et al., 2005) and an 
increased migratory response of dendritic cells after chemokines 
stimulation (Shi et al., 2004).  
About TNFSF14 gene, it is located on 19p13.3 locus, and the protein 
encoded is a member of tumor necrosis factor (TNF) ligands superfamily; 
its receptor (TNFRSF14), also known as Herpesvirus Entry Mediator 
(HVEM), resulted to be associated with CD in one of the latest GWAS 
(Dubois et al., 2010). In murine models, the gene is constitutively 
expressed in inflamed intestinal mucosa (Shaikh et al., 2001). Moreover, 
recent experiments have shown that there is a high expression in human 
intestinal T cells, and that its expression is essential for the production of 
IFN-γ (Cohavy et al., 2004).  
SH2B3 gene encodes for a protein capable to negatively regulate the 
lymphopoiesis and early hematopoiesis, and its down-regulation can lead 
to increased production of B cells, and increased expansion and enhanced 
function of hematopoietic stem cells (HSCs) (Takaki, 2008); it is a negative 
regulator of PDGFR signaling (Gueller et al., 2011). 
TAGAP (T-cell activation GTPase activating protein) gene encodes a 
protein expressed in activated T cells and it’s predicted to function as a 
Rho GTPase-activating protein (Chen et al., 2011).  
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With regard to TNFAIP3 gene, Tnfaip3-/- mice had greater intestinal 
permeability compared to wild-type (Kolodziej et al., 2011), suggesting 
that this protein can maintain intestinal barrier function and support 
epithelial cell tight junctions. It is also closely linked to NF-B pathway 
because failure to down regulate NF-B transcriptional activity resulted in 
chronic inflammation and cell death, as observed in A20-deficient mice 
making TNFAIP3 a potent inhibitor of NF-B signaling  (Wertz et al., 2004). 
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Aim 
The aim of this study is to improve the knowledge about the role of the 
genetics in the CD context, in order to see non-HLA genes not like a list of 
genes with certified immunological function, but to understand the 
reasons why they are associated with CD. 
For this reason the project of the thesis is articulated in several sub-
projects. 
1. Gene Expression studies and non-HLA genes: our aim to improve 
the analyses of candidate gene expression comparing the results 
obtained on mucosal biopsies, peripheral monocytes and T-cell 
lines isolated from duodenal mucosa: three different cell 
populations with three different functions and locations, in order 
to give a picture of the variation in the celiac type and to 
correlate it with a model of CD pathogenesis.  
Moreover, a discriminant analysis of the celiac gene 
expression profile has recently been proposed as a promising 
diagnostic tool with which to distinguish celiac mucosa from 
normal mucosa (Bragde et al.,2011). Therefore, we evaluated the 
diagnostic strength of the discriminant analysis on the gene 
expression data obtained from peripheral blood monocytes with 
the aim to provide a less invasive alternative to duodenal biopsy 
as the only diagnostic tool for CD. 
2. Non-HLA genes and Potential CD patients. Our aim was to 
explore the presence of genetic and expression factors that may 
differentiate potential patients from overt CD patients and 
controls, in particular: 
 To find a different distribution of HLA haplotypes; 
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 To evaluate if there is a different distribution of non-HLA 
genes; 
 To confirm association results also in expression studies on 
RNA extracted from intestinal biopsies.  
 To understand if a correlation exists between genotype 
and expression levels. 
3. Non-HLA genes as a model for risk prediction in a family cohort. 
The aim of this study was to study a genetic risk model for CD 
using HLA and non-HLA risk alleles. We aimed to significantly 
improve the identification of subjects at risk to develop CD by 
modeling the HLA risk with the newly discovered genetic profile 
in order to reach an higher accuracy in prediction. When this goal 
will be reached, families with one case will know, with reliable 
precision, the individual risk of a newborn and will be able to 
anticipate the onset of the clinical phenotype by a simple point-
of-care tests. After families the model might well be extended to 
populations, in the frame of national policies to screen for 
genetic predispositions to diseases. 
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Chapter 1. Non-HLA genes and Celiac Disease: Gene expression studies 
Background and aim 
GWA studies represent a major breakthrough in the genetics of complex 
disorders. At this point, besides the HLA contribution, we know that 39 
genes are associated to CD, but no one knows how these polymorphic 
variants can contribute to the pathogenesis of the disease. Dubois and his 
group (Dubois et al., 2010) performed the largest GWA study in CD history; 
they analyzed 1.469 whole blood samples in an expression quantitative 
trait meta-analysis: 20 out of 38 (52.6%) tested loci had celiac risk variants 
correlated with cis gene expression (Figure 2). 
 
Figure 2: Co-expression analysis of genes mapping in 39 genome-wide significant and 
suggestive CD associated regions in 33.109 heterogeneous human samples from the 
Gene Expression Omnibus (Dubois et al., 2010). 
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The problem is that these analyses were performed on whole blood, but 
literature about an effective correspondence between the association data 
and the gene expression profile in the target tissue is still missing, despite 
it could be useful to explore the mechanisms behind the atrophic 
duodenal outcome. In a recent study (Plaza-Izurieta et al., 2011) in which 
the expression analysis of associated genes was performed on duodenal 
mucosa samples in a Spanish celiac population, correlating it with the 
tagSNP genotype, although the study does not always confirm the 
previous results of eQTL profile (Dubois et al., 2010). 
Moving from these assumptions, our aim is to improve the analyses of 
candidate gene expression comparing the results on mucosal tissue with 
those obtained on peripheral monocytes and T-cell lines isolated from 
duodenal mucosa: three different cell populations with three different 
functions and locations, in order to give a picture of the variation in the 
celiac type and to correlate it with a model of CD pathogenesis.  
Moreover, a discriminant analysis of celiac gene expression profile has 
recently been proposed as a promising diagnostic tool to distinguish celiac 
mucosa from normal mucosa (Bragde et al.,2011). However, only genes 
involved in the alteration of crypt-villi architecture were evaluated and 
only duodenal tissue was tested. Therefore, we evaluated the diagnostic 
strength of the discriminant analysis on the gene expression data obtained 
from peripheral blood monocytes with the aim of providing a less invasive 
alternative to duodenal biopsy as the only diagnostic tool for CD. 
Genes were selected from those resulted to be associated with CD in 
different studies on different populations and so less amenable to an 
environmental effect, in particular KIAA1109, IL-2, IL-21, c-REL, LPP, RGS1, 
SH2B3, TAGAP, TNFAIP3 and TNFRSF14. An additional evaluation was also 
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performed on TNFSF14 mRNA because of the CD-association of its 
receptor TNFRSF14. 
 
Materials and methods 
Patients  
For gene expression analysis, duodenal biopsies were obtained during 
gastroduodenal endoscopy (GDE) procedures and  fresh-frozen in liquid 
nitrogen. At least 10 patients with untreated CD, 3 patients with treated 
CD and 5 non-celiac patients were analyzed. The diagnosis of CD was 
based on ESPGHAN criteria (Working Group of European Society of 
Paediatric Gastroenterology and Nutrition, 1990). Controls included 
patients with a normal duodenal with no mucosal atrophy (Marsh stage of 
lesion M0, (Oberhuber et al., 2001)), they underwent to GDE because of 
Gastritis, Gastroesophageal reflux disease or hypothesis not confirmed of 
Helicobacter Pylori infection.  
 
Monocytes 
We used the Dynabeads® My Pure™ Monocyte kit (Life Technologies, 
Foster City, CA) to isolate monocytes from other peripheral blood cell 
types (B- and T-lymphocytes, NK cells, erythrocytes, dendritic cells etc.). 
Monocytes were extracted from peripheral blood of 18 control patients, 8 
CD patients, 11 Crohn disease patients and 5 celiac patients on a GFD. To 
verify the discriminant results, we analyzed a second cohort of 9 CD 
patients. 
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Gliadin preparation 
Gliadin was extracted from a common exaploid wheat cultivar 
(Sagittario) according to a standard procedure and enzymatically digested 
with pepsin and trypsin, as previously described (Gianfrani et al., 2007). 
PT-gliadin was deamidated with guinea pig tTG.  
 
Generation of gliadin-specific T-cell lines and functional assay 
Gliadin-reactive TCLs were generated from duodenal explants of 3 adult 
control, (non celiacs) and 3 untreated HLA-DQ2+ celiacs, as described 
previously (Gianfrani et al., 2007). Briefly, mucosal explants were digested 
with collagenase-A and cells were suspended at 2-3x105/mL in complete 
medium (X-Vivo15 medium supplemented with 5% AB pooled human 
serum and antibiotics, all provided from BioWhittaker, Verviers, Belgium). 
Mucosal cells were stimulated with 1.5x106 irradiated autologous PBMCs, 
deamidated-PT-gliadin (50 μg/mL), and IL-15 and IL-2 as growth factors 
(R&D System, Minneapolis, MN). After 7 and 21 TCLs were re-stimulated 
with deamidated-PT-gliadin and feeder cells. For gene expression analysis, 
TCLs (0.5-1.0x106) were stimulated with autologous, EBV-transformed B 
lymphoblastoid cell lines (B-LCLs,1.0x106) pulsed overnight in presence or 
absence of deamidated-PT-gliadin (100 μg/mL). After 0, 1, 3 hours of 
incubation, cells were pelleted and cryopreserved at -80°C. Before 
cryopreserving, an aliquot of cell supernatants were harvested for IFN-γ 
measurement. 
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Expression studies 
From frozen tissues samples, total RNA was isolated using RiboPureTM 
kit (Life Technologies, Foster City, CA). The quality of the RNA was assessed 
by running aliquots on agarose gels. In each Real Time PCR experiment, 
double stranded complementary DNA (cDNA) was synthesized from 2 µg 
of total RNA using the High-Capacity cDNA reverse transcription kit (Life 
Technologies, Foster City, CA) as per the manufacturer’s protocol. Retro-
transcription had to be followed by a linear pre-amplification step before 
the Real Time experiment because of the poor amount of RNA recovered 
from monocyte samples. This step was performed using TaqMan® PreAmp 
Master Mix (Life Technologies, Foster City, CA) that preamplifies small 
amounts of cDNA without introducing amplification bias to the sample. 
Experiments were performed on 7900HT Fast Real Time PCR using in 
20µL of reaction TaqMan® Gene Expression Assay 20x (Life Technologies, 
Foster City, CA), TaqMan®Gene Expression Master Mix 2x (Life 
Technologies, Foster City, CA) and about 40ng of cDNA, as per the 
manufacturer’s protocol; each gene expression was normalized towards an 
endogenous housekeeping (GUSb). Relative expression ratios were 
calculated as R =2[Ct(GUSb)-Ct(test)], where R is ratio, Ct is the cycle number at 
the threshold, and test refers to the tested mRNA. The confidence interval 
was fixed at 95%. Data were normalized to the control group.  
All primers and probes for each gene were purchased as commercial 
’Assays-On-Demand’ sets from Life Technologies (Foster City, CA), chosen 
because of their gene target position: probe binds and amplifies an exonic 
junction, which can permit us to exclude from our analysis any DNA 
genomic contaminants. 
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Statistical Analysis 
The non-parametric Mann-Whitney U test for 2 independent variables was 
used to assess the difference between data sets. Statistical analyses were 
performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and GraphPad 
Prism 5.0 (GraphPad software, San Diego, CA, USA). 
 
 
Results 
Expression studies  
Mucosal tissue 
KIAA1109 and c-REL mRNA expression in intestinal mucosa of CD 
patients was not significantly different from controls, while the expression 
increased significantly in CD-GFD mucosa compared to controls (p=0.01, 
Mann-Whitney U: 13.00 and p<0.01,  Mann-Whitney U: 5.000 respectively) 
and CD patients (p=0.03, Mann-Whitney U: 9.00 and p=0.01, Mann-
Whitney U: 4.000 respectively) (Figure 3a-b). On the contrary, IL 21 gene 
was more expressed in CD patients than in controls (p=0.01, Mann-
Whitney U: 3.00; Figure 3c) according to data reported in literature (Fina 
et al., 2008); this increase seems to be gluten-dependent because the 
expression returned to the levels of controls after at least one year of GFD 
(CD vs. CD-GFD p=0.01, Mann-Whitney U: 0.00). Also SH2B3 gene showed 
a mild not significant increase of gene expression in CD duodenal biopsies 
while in CD-GFD the expression decreased sharply in a significant way 
compared to both controls (p<0.01, Mann-Whitney U: 3.00) and CD 
(p<0.01, Mann-Whitney U: 2.00) (Figure 3d). In our studies TAGAP mRNA 
significantly increased in CD mucosal biopsies compared to controls 
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(p=0.04, Mann-Whitney U: 23.00) (Figure 3e). Mucosal biopsies of CD 
patients showed higher values of TNFSF14 mRNA than controls (p<0.01, 
Mann-Whitney U: 8.00), and it is noteworthy that these levels remain high 
in CD-GFD patients when compared to Controls (p=0.04, Mann-Whitney U: 
9.00) (Figure 3f). 
  29 
 
 
KIAA1109
Ctr CD GFD
0
2
4
6 p=0.01
R
Q
REL
Ctr CD GFD
0.0
0.5
1.0
1.5
2.0
2.5
p=0.01
p=0.01
R
Q
IL21
Ctr CD GFD
0.1
1
10
100
1000 p<0.001
p=0.01
L
o
g
R
Q
SH2B3
Ctr CD GFD
0
2
4
6
p<0.001
p<0.001
R
Q
TAGAP
Ctr CD GFD
0
5
10
15
p=0.04
R
Q
TNFSF14
Ctr CD GFD
0
5
10
15
20 p=0.04
p<0.001
R
Q
a)
f)e)d)
c)b)
 
Figure 3. Gene expression studies on small intestinal biopsies. 
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The analysis of IL-2 mRNA showed that there were no significant 
differences among CD patients, controls and CD-GFD; in particular a trend 
of slight over-expression was shown in CD compared to Controls and CD-
GFD patients. The analyses of  LPP, RGS1, TNFAIP3 and TNFRSF14 showed 
no significant differences between controls, CD and CD-GFD patients, 
nevertheless RGS1 gene expression was slightly improved in CD compared 
to controls, even if this difference did not reach the significant threshold. 
All these last results are resumed in Figure 4. 
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 Figure 4. Gene expression studies on mucosal tissue of IL-2, LPP, RGS1, TNFAIP3 and 
TNFRSF14 genes. 
 
Peripheral blood monocytes 
The expression of the panel of candidate genes was evaluated in 
monocytes extracted from peripheral blood samples of 18 controls, 17 CD 
and 5 CD-GFD patients. The aim was to evaluate the differences with the 
results obtained in duodenal mucosa, and to investigate the involvement 
of these genes in peripheral processes also, for example, before the 
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recruitment of monocytes from the blood to intestinal tissue. Monocytes 
extracted from peripheral blood of 11 Crohn patients served as positive 
controls. We did not evaluate the expression of IL-2 and IL-21 because 
they are not produced by monocytes but by CD4+ TCLs after antigen 
activation (De Nitto et al., 2009; Williams et al., 1991). 
The KIAA1109 gene was over-expressed in CD (t-test p=0.05; Means ± 
SEM "0.8650 ± 0.04832 N=18" vs. "1.068 ± 0.08723 N=17"), Crohn (t-test 
p=0.02; Means ± SEM "0.8650 ± 0.04832 N=18" vs. "1.435 ± 0.2794 N=11") 
and CD-GFD patients versus controls (t-test p=0.05; Means ± SEM "0.8650 
± 0.04832 N=18" vs. "1.110 ± 0.1445 N=5"; Figure 4a). Differently, c-REL, 
SH2B3 and LPP expression was lower in CD monocytes compared with 
controls (c-REL – p<0.01; Mann-Whitney U 11.50; SH2B3 – t-test p=0.05; 
Means ± SEM "1.097 ± 0.1163 N=17" vs. "0.7500 ± 0.1153 N=15"; LPP – 
p=0.05; Mann-Whitney U 80.0), but regarding c-REL and SH2B3 genes 
significantly higher than in either CD-GFD (c-REL – t-test p<0.01; Means ± 
SEM "0.9612 ± 0.08464 N=17" vs. "2.812 ± 0.4869 N=5"; SH2B3 – t-test 
p<0.01; Means ± SEM "1.097 ± 0.1163 N=17" vs. "2.448 ± 0.2510 N=4") or 
Crohn monocytes (c-REL – p<0.01;  Mann-Whitney U: 10.0; SH2B3 – t-test 
p=0.01; Means ± SEM "1.097 ± 0.1163 N=17" vs. "1.895 ± 0.3358 N=11") 
(Figure 4b, 4c and 4e). The expression of RGS1 showed a trend similar to 
that of c-REL, but did not differ between CD-GFD and control monocytes 
(Figure 4d). The ANOVA revealed a significant difference between the 
groups in terms of mean RQ as regards c-REL, SH2B3 and TNFRSF14 
expression. In all cases the p-value was lower than 0.01) 
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 Figure 5. Gene expression studies on peripheral blood monocytes of KIAA1109, c-REL, 
LPP, RGS1 and SH2B3 genes. 
 
 
TAGAP, TNFSF14 and TNFRSF14 were expressed at similar levels in CD 
and CD-GFD monocytes and results are resumed in Figure 6. 
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Figure 6. Gene expression studies on peripheral blood monocytes of TAGAP, TNFSF14 
and TNFRSF14 genes. 
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T-cell lines isolated from duodenal biopsies. 
We isolated CD4+ TCLs from the duodenal mucosa of 3 controls and 3 CD 
patients, raised against deamidated PT-gliadin digest. Only CD-derived 
TCLs highly reactive to deamidated PT-gliadin were selected. To evaluate 
gene expression in terms of gliadin dependence and/or time dependence, 
TCLs were grown in a culture medium with or without deamidated PT 
gliadin and fixed at baseline (time 0) and after 1h and 3h of incubation. We 
labeled these conditions as follows: M0=medium culture at 0h; 
M1=medium culture after 1h; M3=medium culture after 3h; G0=gliadin 
culture at 0h; G1=gliadin culture after 1h-incubation; G3=gliadin culture 
after 3h-incubation. 
Samples were analyzed at time 0h and 3h to determine at which time-
point the expression changes occurred. The expression at 1 h was 
evaluated only if differences were found between baseline and 3 h. As 
expected, there was no difference in terms of gene expression in controls 
at time 0, incubated with or without gliadin (controls M0 vs controls G0), 
or in CD samples at time 0, incubated with or without gliadin (CD M0 vs CD 
G0).  
IL-2 expression differed significantly between CD and controls already at 
time 0, irrespective of the presence of gliadin in the culture medium (CD 
M0/G0 vs controls M0/G0). After 1 and 3h of incubation, gliadin 
significantly stimulated IL-2 mRNA expression, whereas at the same time 
points, in the absence of gliadin, IL-2 expression was significantly lower in 
CD than in control samples (Figure 7A). IL-21 expression at baseline was 
similar in CD and controls in both T-cell populations incubated with and 
without gliadin (CD M0/G0 vs controls M0/G0). After exposure to gliadin 
for 1h and for 3h, IL-21 expression was higher in the CD group than in 
controls (CD G1 vs controls M0/G0 and CD M0/G0). Interestingly, IL-21 
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expression was higher in celiac TCLs after incubation for 3h in medium 
alone (CD M3 vs controls M0; Figure 7B). Similar to IL-21, the expression of 
c-REL at baseline in CD and in controls did not differ between the two T-
cell populations incubated with and without gliadin (CD M0/G0 vs controls 
M0/G0). At 1h, c-REL expression increased slightly in control and CD TCLs, 
irrespective of gliadin (CD M1/G1vs controls M0/G0), whereas after 3h of 
incubation, c-REL expression  was higher in CD than in control TCLs, and 
the difference was more pronounced in the presence of gliadin (control 
M3/G3 vs CD M3 and G3) (Figure 7C). TNFAIP3 expression was similar to 
that of c-REL, except for an increase in expression in CD TCLs after 1h of 
incubation (Figure 7D). RGS1 gene expression was much lower in CD than 
in control TCLs at time 0, irrespective of the presence of gliadin in the 
medium (CD M0/G0 vs controls M0/G0); it remained lower also after 1h 
and 3h of incubation with medium alone. After 3h of incubation with 
gliadin, the expression of TNFAIP3 was up-regulated and reached a level 
comparable to that of controls in the same condition (Figure 7E).  
No difference in the expression of any gene was found in control TCLs 
up to three hours of incubation with and without gliadin (data not shown). 
All the significant differences have positive Mann-Whitney test (p=0.05). 
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 Figure 7: gene expression studies on T-cell lines isolated from duodenal biopsies of IL-
2, IL-21, c-REL, RGS1 and TNFAIP3 genes. 
 
The expression of KIAA1109, LPP, SH2B3, TAGAP, TNFSF14 and 
TNFRSF14 did not differ between CD in samples incubated with and 
without gliadin measured at 0h, and 3h. Hence we did not measure their 
expression after 1h of incubation (Figure 8). 
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Statistical Analyses 
Discriminant Analysis in small intestinal tissue 
In order to identify genes whose expression in small intestinal mucosa 
better characterize celiac tissue versus controls, a linear discriminant 
equation was fitted to the standardized values of expression (RQ). At each 
step, the variable that minimizes the overall Wilks' Lambda is entered. The 
following limits were used for the analysis:  
a. Maximum number of steps is 12 
b. Minimum partial F to enter is 1.84 
c. Maximum partial F to remove is 1.71 
According to this analysis, 5 genes (stepwise: TNFAIP3, IL-21, c-REL, RGS1 
and LPP) were selected from those analyzed, with a significant p-value 
always lower than 0.001 (Table 3). 
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Step 
Candidate 
Gene 
Wilks' 
Lambda 
Exact F 
p-
value 
1 TNFAIP3 0.404 59.002 <0.001 
2 IL-21 0.300 45.521 <0.001 
3 c-REL 0.261 35.809 <0.001 
4 RGS1 0.235 30.143 <0.001 
5 LPP 0.222 25.272 <0.001 
Table 3. Results of Discriminat analysis in the small intestinal tissue: five genes 
significantly contribute to the discriminant analysis by a stepwise process. It means that 
the expression values in the intestinal tissue of TNFAIP3, IL-21, c-REL, RGS1 and LPP 
genes, it is possible to discriminate the celiac type from the control one. 
 
 
By multiplying the unstandardized canonical discriminant coefficients to 
the actual values of the expression of the genes listed in the table, a 
discriminant score is obtained for each individual, which allows the 
classification into the diagnostic groups.  
 
        (             )  (           )  (     
      )  (          )  (         )           
 
By applying the discriminant equation to cases and control a classification 
table was produced (Table 4) which shows the capacity of the equation to 
discriminate celiacs from controls, in fact 92.9% of original cases were 
correctly classified (90% of controls and 95.9% of celiacs).  
 
  
Predicted Group 
Membership 
 
  Control Celiac  
Real Group 
Membership 
Control 19 (95%) 1 (5%) 20 
Celiac 2 (9.1%) 
20 
(90.9%) 
22 
  21 21 42 
Table 4. Classification results of discriminant analysis: by applying the results of 
Wilks’ Lambda discrimination analysis, a classification table was produced and the 
results compared with the real group membership of the considered samples. As 
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described, 92.9% of samples (90% of controls and 95.9% of celiacs) were correctly 
classified. 
 
Discriminant analysis in peripheral blood monocytes 
Encouraged by the results obtained with for  duodenal mucosa, we 
developed a similar linear discriminant analysis for the gene expression in 
peripheral blood monocytes. We randomly divided our celiac and control 
cases into two balanced groups. By stepwise statistic entered the 
expression of four candidate genes were selected by multivariate analysis 
of CD, similar to the results obtained in the duodenal tissue. LPP, c-REL, 
KIAA1109 and TNFAIP3 well discriminated between cases and controls, 
and the discriminant function revealed a very low Wilks’ lambda (0.048). 
Indeed 91% of controls and all CD patients were correctly predicted. 
To verify these results we applied the discriminant equation obtained in 
the training set, constituted by 9 CD patients and 11 controls, to develop 
the discriminant equation, to the gene expression of a new cohort of 
patients (“validation set”) constituted by 7 controls, 8 CD, 5 CD-GFD 
patients and 9 Crohn patients as positive controls of inflammation. The 
expression RQ of each individual was multiplied by the unstandardized 
coefficient obtained with the training set. The D-score was obtained as 
explained previously. We obtained four clustered D-scores, one for each 
group (Controls, CD, Crohn and CD on gluten free diet, Figure 9) with no 
overlap among them. The very low Wilk’s lambda obtained by the selected 
genes, closed to 0=complete discrimination, guarantees the confidence 
into the classification capacity of the equation in the clinical setting. Figure 
9 shows the distribution of the D-Scores of CD, and CD patients on GFD, 
controls and Cohn’s disease patients. The D-Score for active celiac patients 
was negative in all cases, while it was positive for all the other groups on 
differentiated clusters. 
  39 
 
 
Figure 9. Distribution of the Discriminant of CD, Controls, Crohn and CD-GFD patients. 
The D-score clearly separated the four groups of subjects evaluated. Only CD patients 
had a negative D-score. The D-score of CD-GFD patients was intermediate between the 
scores of controls and Crohn patients. 
 
This score allows indeed to compute a group membership probability 
for each individual, we were allowed so to classify correctly all controls 
and CD patients; none of the controls, neither CD on GFD nor Crohn 
patients were mis-classified as CD patients (Table 5). 
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Case 
Number 
Actual 
Group 
Highest Group 
Discriminant 
Score 
Predicted 
Group 
P(D>d | 
G=g) 
P(G=g 
| D=d) 
Squared 
Mahalanobis 
Distance to 
Centroid 
Function 1 
p df 
1 Celiac Celiac 0.000 1 0.878 14.940 0.076 
2 Celiac Celiac 0.222 1 1.000 1.491 -2.568 
3 Celiac Celiac 0.774 1 1.000 0.082 -3.503 
4 Celiac Celiac 0.844 1 1.000 0.038 -3.986 
5 Celiac Celiac 0.882 1 1.000 0.022 -3.641 
6 Celiac Celiac 0.463 1 1.000 0.538 -3.056 
7 Celiac Celiac 0.101 1 1.000 2.695 -5.431 
8 Celiac Celiac 0.581 1 1.000 0.305 -4.341 
9 Control Control 0.089 1 1.000 2.884 6.119 
10 Control Control 0.000 1 0.576 16.548 0.353 
11 Control Control 0.566 1 1.000 0.330 4.995 
12 Control Control 0.126 1 1.000 2.346 2.889 
13 Control Control 0.826 1 1.000 0.048 4.201 
14 Control Control 0.642 1 1.000 0.216 3.956 
15 Control Control 0.955 1 1.000 0.003 4.364 
16 Crohn Control 0.002 1 1.000 9.216 7.457 
17 Crohn Control 0.000 1 1.000 326.316 22.485 
18 Crohn Control 0.000 1 1.000 111.285 14.970 
19 Crohn Control 0.000 1 1.000 1232.648 39.530 
20 Crohn Control 0.000 1 1.000 5440.147 78.178 
21 Crohn Control 0.000 1 1.000 2193.662 51.257 
22 Crohn Control 0.000 1 1.000 2997.302 59.169 
23 Crohn Control 0.000 1 1.000 885.652 34.181 
24 Crohn Control 0.000 1 1.000 8543.655 96.853 
25 CD-GFD Control 0.232 1 1.000 1.431 5.617 
26 CD-GFD Control 0.000 1 1.000 532.145 27.489 
27 CD-GFD Control 0.000 1 1.000 241.667 19.967 
28 CD-GFD Control 0.000 1 1.000 344.648 22.986 
29 CD-GFD Control 0.000 1 1.000 959.294 35.393 
Table 5. Validation of the discriminant analysis. The analysis conducted to classify 
controls, CD, Crohn and CD-GFD patients in 2 groups: Controls and Celiacs. The Highest 
Group corresponds to the first prediction choice, and the Second Highest Group to the 
second one. Effective control and celiac patients were all correctly predicted; Crohn and 
CD-GFD patients were predicted as controls. 
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Discussion 
Our previous works on genetic risk models and potential CD (Izzo et al., 
2011; Sperandeo et al., 2011) reinforce the selection of a small set of 
candidate genes with specific functions most likely related to the 
pathogenesis of CD. Indeed the main reason why gene expression studies 
rarely produce significant clinical predictions is the overwhelming 
abundance of data. Hundreds of gene over- or under-expressed in the 
disease status compared to the healthy status very often reflect the 
inflammation and the expected immune response, but rarely point to the 
pathogenic profile of the disease. 
Thanks to the recently proposed new ESPGHAN diagnostic algorithm for 
CD, (Husby et al., 2012) duodenal biopsy can now be avoided in a sizeable 
proportion of patients on the basis of clinical symptoms and high 
production of anti-tTG antibody. Unfortunately, it is not possible to 
generalize the method because not all CD patients have high anti-tTG 
levels (i.e. Potential Celiac Disease), and many patients are asymptomatic.  
Moreover, this new protocol is not applicable for at-risk relatives (Husby et 
al., 2012).  
By virtue of this, the aim of this study was: firstly, to build a panoramic 
view on the gene expression profile of some of the most associated CD 
related genes, exploring it at different levels (i.e. mucosal biopsies, 
peripheral monocytes and TCLs). Secondly, to use the gene expression 
profile of CD-associated genes in peripheral blood monocytes to 
differentiate patients affected by CD from controls as a step towards the 
molecular diagnosis of the disease. 
First of all we demonstrated that some gene expression profile are 
modified according to the healthy state of the patients (e.g. Differences 
between gene expression in celiacs and not celiacs patients), in several 
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cases it was ascribable to the inflammation state of the analyzed tissue 
and/or cell lines analyzed (comparing gene expression on monocytes of CD 
and Crohn patients used as positive inflammation controls), in many cases 
it has been possible to hypothesize to assign the perturbation state to the 
CD genetic state, because of the similar phenotype between celiacs and 
CD-GFD patients.  
It is noteworthy that KIAA1109 gene expression is over activated in 
mucosal biopsies of CD-GFD patients and that in these patients it remains 
higher than controls also at peripheral level, and comparable with that of 
CD and Crohn. Is this case is very hard to hypothesize the role of this 
(probable) endonuclease, what is clear is that the same behavior that we 
checked for CD and Crohn in monocytes suggest us a reasonable 
mechanism inflammation but not gliadin exposure dependent.  
Conversely, for c-REL, SH2B3 and RGS1 at peripheral level we found a 
different gene expression in CD compared with both controls and Crohn. 
These findings are important mostly for c-REL genes, because we 
demonstrated that, by virtue of the involvement of this protein in NF-B 
pathway, the inflammation impairment occurs not only at tissue target but 
also at peripheral level. Regarding c-REL and SH2B3 we did confirm an 
alteration also at intestinal mucosa level; conversely this is not true for 
RGS1 gene, which expression is particularly altered in mucosa-derived 
TCLs. It is important to highlight these findings because RGS1 gene 
encodes a member of G protein signaling regulator family which is 
probably involved in homing mechanism. In fact Rgs1-/- mice showed an 
increased B cell movement from and towards lymph nodes (Han et al., 
2005) and an increased migratory response of dendritic cells after 
chemokines stimulation (Shi et al., 2004). Interestingly in our studies,  
RGS1 gene is down-regulated at basal level in celiac T cell clones, and its 
levels become higher than controls after 3h-incubation with gliadin 
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peptides but not with medium only: these findings demonstrate that (i) 
RGS1 is directly regulated by gliadin peptides; (ii) CD patients have an 
altered homing mechanism which should be deeper investigated. 
Surprising, very positive results were from gene expression on 
peripheral monocytes, so the second step of our work has been to use the 
information provided from gene expression profile to build a prognostic 
(and hopefully diagnostic) equation able to discriminate celiac type from 
the control one. Using a discriminant analysis, here we demonstrate that 
the expression of a small set of candidate genes in peripheral blood 
monocytes can be used to correctly classify CD patients from controls and 
from patients affected by Crohn disease, without considering HLA and 
anti-tTG levels. In fact, the procedure we used resulted in a distance 
between groups that is unusual with ordinary diagnostic tools (very low 
Wilk’s lambda). We did not add anti-tTG antibodies or HLA data for each 
individual because it is well recognized that the former has a very high 
sensitivity and specificity, and the latter has a very high negative predictive 
value. Since we reached a correct diagnostic classification in the validation 
set (above 95%) by gene expression data only, we would have shown 
overoptimistic estimate by adding the anti-tTG values. But, this should be 
done in clinical practice in order to increase the sensitivity and the 
specificity of the diagnosis when duodenal biopsy is not available. 
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Chapter 2. Non-HLA genes and Celiac Disease: Potential CD patients 
Backgroun and aim 
Recently the clinical presentation of CD underwent substantial changes: 
from classical malabsorption to light or absent symptoms associated to 
moderate damage of intestinal mucosa. The term ‘potential CD’ was 
assigned to individuals with proper DQ2 or DQ8, production of anti tTG, 
normal small intestinal mucosa (Figure 10), classified as Marsh 0 (no 
damage) or Marsh 1 stage (unspecific intra epithelial infiltration only). 
These are also defined “serological positive cases” (Koskinen et al., 2008; 
Kurppa et al., 2010). Potential patients suggest that the development of 
adaptive anti-gluten immunity is not sufficient to develop villous atrophy. 
This is supported by animal models showing that inflammatory gluten-
induced responses are not sufficient to develop mucosal lesions. Thus, we 
can subgroup individuals into three groups: controls, patients who 
developed antibodies but no intestinal lesions (M0 and M1 potentials) and 
patients with antibodies and villous atrophy (overt CD). Analyzing 
differences among these subgroups may shed light into the genes 
differentially involved in the development of adaptive gluten-induced 
immunity and of the tissue lesions (different between potential and CD), as 
well as genes involved in all steps of CD pathogenesis (different between 
control and potential, and potential and CD). 
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Figure 10: duodenal mucosa of a Potential CD patient. 
 
We have a sizeable cohort of a living experimental model of CD: 
intestinal production of anti-tTG antibodies but no specific mucosal 
damage. The majority of these individuals have no symptoms and may be 
grouped into low-medium-high anti-tTG producers, but all have a small 
intestinal mucosa with normal villi/crypt ratio, none or moderate IEL 
infiltration and normal epithelial layer. Over a prolonged follow up on 
gluten containing diet only about 1/3rd develop mucosal damage, most 
frequently not associated to symptoms (Tosco et al., 2011). The reasons 
why potential CD do not show any degree of substantial mucosal damage, 
albeit the presence of all the features of CD, is the question, whose answer 
can contribute to the understanding of the pathogenesis of CD. 
Our aim was to explore the presence of genetic and expression factors 
that may differentiate potential patients from overt CD patients and 
controls, in particular: 
 To find a different distribution of HLA haplotypes; 
 To evaluate if there is a different genotypic distribution of non-
HLA; 
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 To confirm association results also in expression studies on 
RNA extracted from intestinal biopsies.  
 To understand if a correlation exists between genotype and 
expression levels. 
A further step was to evaluate if these analysis could be applied in order 
to compare potentials CD cases which developed and those which not 
developed villous atrophy after a three years-follow up program (Tosco et 
al., 2011). 
 
Methods 
Subjects 
1. 127 patients from southern Italy (median age 6 years and 6 
months, range 18 months-16 years) were classified as ‘potential 
CD cases’ on the basis of: 
 Increased levels of anti-tTG (IgA anti Human Tissues 
Transglutaminase) and Anti-Endomisium positive. Serum 
EMA and anti tTG IgA were detected by indirect 
immunoﬂuorescence and by enzyme-linked immunosorbent 
assay (ELISA) technique using a kit based on human 
recombinant antigen respectively (Eu-tTg IgA Kit, Eurospital, 
Trieste). 
 Normal architecture of the small intestinal mucosa (Marsh 0 
and Marsh 1 stages) on at least four mucosa samples, to 
minimize the possible bias due to patchy lesions. Definition 
of the stage of lesion was obtained by Marsh stages 
modified by Oberhuber (Tosco et al., 2011). 
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After a three years follow-up, 11 potential CD patients 
developed villous atrophy. 
2. To evaluate the HLA related risk haplotypes, the 127 potential 
cases were compared to a set of 311 overt cases from the same 
population described above and reported in Bourgey et al 
(Bourgey et al., 2007). 
3. To evaluate non-HLA related risk alleles, a cohort of 643 overt 
CD cases, and 711 controls were compared to the 127 potential 
CD patients: in particular, genotyping of the candidate genes on 
4q27 locus was performed on a set of about 350 cases and about 
450 controls from the above sample. All tested cases originated 
from the same centre and the same geographical area in order 
to minimize the bias due to the population stratification. 
Controls were randomly selected from a DNA bank representing 
the healthy population of the region. 
 
Genotyping 
HLA typing was performed using Eu-Gene Risk kit (EUROSPITAL, Trieste, 
Italy). Cases were grouped into 5 HLA (double DQ2, DQ2 in trans, DQ2 
single, DQ8 + DQB1*02, No DQ2or DQ8), as previously reported (Bourgey 
et al., 2007; Margaritte-Jeannin et al., 2004). 
Thirteen SNPs (rs6441961, rs17810546, rs1738074, rs917997, 
rs2816316, rs1464510, rs2327832, rs842647, rs6822844, rs4374642, 
rs13119723, rs1127348, rs6840978) were genotyped using TaqMan 
technology (Life Technologies, Foster City, CA) (Table 6). Reactions were 
performed on 7900HT Fast Real-Time PCR System (Life Technologies, 
Foster City, CA) in a volume of 20 μL, containing SNP master mix, TaqMan 
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assays and about 50 ng of genomic DNA template. Each plate also 
contained genotyping controls (4 duplicates of 4 CEPH DNA). 
Chr Gene SNP 
1 RGS1 rs2816316 
2 IL18RAP rs917997 
2 REL rs842647 
3 SCHIP rs17810546 
3 LPP rs1464510 
3 CCR rs6441961 
4 
KIAA1109 
rs1127348 
4 rs13119723 
4 rs4374642 
4 IL2 rs6822844 
4 IL21 rs6840978 
6 OLIG3 rs2327832 
6 TAGAP rs1738074 
Table 6. SNPs analyzed in our cohort 
 
Statistical Analysis 
Frequencies were compared by the χ2 test with 0.05 probability of the 
null hypothesis. Skewed variables were log transformed when required. 
Expression data were compared by a signed Rank test for independent 
samples. Data analysis was performed using: Prism (GraphPad Software, 
San Diego, CA), SPSS 15 (SPSS Inc., Chicago, IL, USA) and Haploview 4.1. 
 
Results 
HLA typing 
The HLA genotype of 127 potential CD cases was compared to that of 
311 Celiacs previously reported by us (Bourgey et al., 2007) (Table 7 and 
8).  
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HLA 
Haplotype 
DQA1-DQB1 
Linkage DR Allele 
DQ2.5 DQA1*05-DQB1*0201 DR3 
½ DQ2  
in trans 
DQA1*02-DQB1*0202 DR7 
½ DQ2  
in cis 
DQA1*05-DQB1*03 DR5 
DQ8 DQA1*0301-DQB1*0302 DR4 
DQX ALTRE DRX 
Table 7. HLA haplotypes associated with CD. 
DQ DR in linkage HLA risk Group 
DQ2.5/DQ2.5 
DQ2.5/DQ2.2 
DR3/DR3 
DR3/DR7 
Group 1 
DQ7/DQ2.2 DR5/DR7 Group 2 
DQ2.5/DQ7 
DQ2.5/DQ8 
DQ2.5/DQX 
DR3/DR5 
DR3/DR4 
DR3/DRX* 
Group 3 
DQ2.2/DQ2.2 
DQ2.2/DQ8 
DQ8/DQ8 
DR7/DR7 
DR7/DR4 
DR4/DR4 
Group 4 
DQ2.2/DQX 
DQ7/DQ7 
DQ7/DQX 
(more frequent) 
DR7/DRX* 
DR5/DR5 
DR5/DRX* 
Group 5 
X* different from 3, 4, 5, 7 
Table 8. Classification according to the HLA genotype (Bourgey et al., 2007). DQ2.5 → 
DQA1*05 – DQB1*0201; DQ2.2 → DQA1*02 – DQB1*0202; DQ7 → DQA1*05 – 
DQB1*03; DQ8 → DQA1*0301 – DQB1*0302 
 
Potential CD less frequently belong to high risk classes, while they show 
more frequently very low or moderate HLA-related risk (Figure 11). We 
found a significant HLA distribution in Potential CD cases versus celiacs 
(χ2=48.42 p<0.001). When we compared the HLA risk between M0 and M1 
potential cases we did not observe any difference (χ2 =1.92; p=0.75, data 
not shown). Cases who developed small intestinal atrophy during follow 
up did not show an HLA distribution different from those who remained 
potential (χ2 =5.17; p=0.27, data not shown). 
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Figure 11. Distribution of HLA haplotypes in Potential CD and CD cases according to 
the risk groups described in Bourgey et al, 2007 (Bourgey et al., 2007). 
 
Eight candidate genes SNPs genotype and allele distribution 
Hunt et al. (Hunt et al., 2008) reported 8 new CD risk loci, located on 
different chromosomes. Although we know that the size of the sample of 
the potential CD has no sufficient power to differentiate the 
polymorphism’s distribution, we found significant results in the genotype 
and allele distribution when we compared Potential CD versus controls and 
CD cases.  
From a genotypic point of view, Potential CD show a different 
distribution of the SNPs located in c-REL and CCR genes versus control; 
seven out of 8 SNPs, showed no significant differences between potential 
and CD cases in their genotype distribution, but there was a significant 
difference of the SNP in c-REL gene also in this case (Table 9). 
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  Controls Potential CD χ2 p value CD cases Potential CD χ2 p value 
RGS1 
(rs2816316) 
AA 488 (68,6%) 88 (69.3%) 
0.32 0.85 
463 (72,7%) 88 (69.3%) 
2.67 0.26 AC 193 (27.1%) 35 (27.6%) 166 (26.1%) 35 (27.6%) 
CC 30 (4.2%) 4 (3.1%) 8 (1.3%) 4 (3.1%) 
          
IL18RAP 
(rs917997) 
AA 42 (5.9%) 7 (5.5%) 
1.07 0.58 
41 (6.4%) 7 (5.5%) 
0.69 0.71 AG 246 (34.6%) 50 (39.4%) 227 (35.6%) 50 (39.4%) 
GG 423 (59.5%) 70 (55.1%) 369 (57.9%) 70 (55.1%) 
          
LPP 
(rs1464510) 
AA 108 (15.2%) 28 (22.0%) 
7.58 0.02 
152 (23.9%) 28 (22.0%) 
0.77 0.68 AC 362 (50.9%) 70 (55.1%) 324 (50.9%) 70 (55.1%) 
CC 241 (33.9%) 29 (22.8%) 161 (25.3%) 29 (22.8%) 
          
OLIG3 
(rs2327832) 
AA 480 (67.7%) 84 (66.7%) 
0.05 0.98 
399 (63.6%) 84 (66.7%) 
0.81 0.67 AG 202 (28.5%) 37 (29.4%) 208 (33.2%) 37 (29.4%) 
GG 27 (3.8%) 5 (4.0%) 20 (3.2%) 5 (4.0%) 
          
TAGAP 
(rs1738074) 
AA 125 (17.6%) 26 (20.5%) 
0.6 0.74 
144 (22.6%) 26 (20.5%) 
0.36 0.84 AG 354 (49.9%) 61 (48.0%) 305 (47.9%) 61 (48.0%) 
GG 231 (32.5%) 40 (31.5%) 188 (29.5%) 40 (31.5%) 
          
c-REL 
(rs842647) 
AA 404 (56.8%) 62 (48.8%) 
9.84 0.01 
359 (56.4%) 62 (48.8%) 
10.8 0.01 AG 272 (38.3%) 50 (39.4%) 249 (39.1%) 50 (39.4%) 
GG 35 (4.9%) 15 (11.8%) 29 (4.6%) 15 (11.8%) 
          
CCR 
(rs6441961) 
AA 99 (13.9%) 25 (19.7%) 
8.28 <0.01 
120 (18.8%) 25 (19.7%) 
2.29 0.32 AG 318 (44.7%) 66 (52.0%) 293 (46.0%) 66 (52.0%) 
GG 294 (41.4%) 36 (28.3%) 224 (35.2%) 36 (28.3%) 
          
SCHIP1 
(rs17810546) 
AA 610 (85.8%) 102 (80.3%) 
2.56 0.28 
526 (82.6%) 102 (80.3%) 
0.92 0.63 AG 92 (12.9%) 23 (18.1%) 106 (16.6%) 23 (18.1%) 
GG 9 (1.3%) 2 (1.6%) 5 (0.8%) 2 (1.6%) 
Table 9. Genotypic distribution of 8 non-HLA SNPs in Potential CD versus controls and 
celiac cases. 
By the analysis of the allele distribution, we found that both LPP*A, c-
REL*G, and CCR*A alleles were significantly associated to potential cases 
compared to controls (Table 10). Only c-REL*G allele was significantly 
associated with potential cases when compared to CD cases (Table 10). 
Although RGS1 and CCR produced an interesting difference (in term of χ2 
which is 1.31 and 1.61 respectively), they could not reach the statistical 
significance (Table 10).  
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Potential CD and controls 
SNP Locus A1 A2 
Pot CD 
Cases, 
Controls 
Ratios 
MAF 
Pot CD 
cases 
MAF 
controls 
χ
2
 
p 
value 
Odds ratio 
(95% 
confidence 
interval) 
rs2816316 RGS1 A C 
214:44, 
1169:253 
0.17 0.18 0.08 0.77 1.05 (0.74-1.50) 
rs917997 IL18RAP G A 
193:65, 
1092:330 
0.25 0.23 0.48 0.49 0.90 (0.66-1.22) 
rs1464510 LPP C A 
129:129, 
844:578 
0.50 0.41 7.84 0.01 0.68 (0.52-0.89) 
rs2327832 OLIG3 A G 
207:49, 
1162:256 
0.19 0.18 0.17 0.68 0.93 (0.66-1.31) 
rs1738074 TAGAP G A 
143:115, 
816:604 
0.44 0.42 0.37 0.54 0.92 (0.70-1.20) 
rs842647 c-REL A G 
178:80, 
1080:342 
0.31 0.24 5.62 0.02 0.70 (0.53-0.94) 
rs6441961 CCR G A 
139:119, 
906:516 
0.46 0.36 8.99 <0.01 0.66 (0.51-0.87) 
rs17810546 SCHIP1 A G 
231:27, 
1312:110 
0.10 0.08 2.17 0.14 0.72 (0.46-1.12) 
Potential CD and CD cases 
SNP Locus A1 A2 
Pot CD 
cases. 
CD cases 
Ratios 
MAF 
Pot CD 
cases 
MAF 
CD 
cases 
χ
2
 
p 
value 
Odds ratio 
(95% 
confidence 
interval) 
rs2816316 RGS1 A C 
214:44, 
1092:182 
0.17 0.14 1.31 0.25 0.81 (0.56-1.16) 
rs917997 IL18RAP G A 
193:65, 
965:309 
0.25 0.24 0.10 0.75 0.95 (0.70-1.29) 
rs1464510 LPP C A 
129:129, 
646:628 
0.50 0.49 0.04 0.83 0.97 (0.74-1.27) 
rs2327832 OLIG3 A G 
207:49, 
1008:248 
0.19 0.20 0.05 0.82 1.04 (0.74-1.46) 
rs1738074 TAGAP G A 
143:115, 
681:593 
0.44 0.46 0.34 0.56 1.08 (0.83-1.42) 
rs842647 c-REL A G 
178:80, 
967:307 
0.31 0.24 5.43 0.02 0.71 (0.53-0.95) 
rs6441961 CCR G A 
139:119, 
741:533 
0.46 0.42 1.61 0.20 0.84 (0.64-1.10) 
rs17810546 SCHIP1 A G 
231:27, 
1158:116 
0.10 0.09 0.47 0.49 0.84 (0.55-1.33) 
Table 10. Allelic distribution of 8 non-HLA SNPs in Potential CD versus controls and 
celiac cases. 
 
None of the candidate genes distinguished between M0 and M1 
potential cases. M0 Potential CD cases were not different from controls, 
except for the CCR gene. M1 patients reinforced the significant differential 
distribution of the c-REL genotype when compared to CD: again the GG 
genotype was about three times more frequent in M1 patients compared 
to CD patients. The same trend, with good statistical significance, is 
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observed between M1 potential and controls not only for c-REL but also 
for LPP gene (Table 11). 
  Controls 
Potential 
M0 
Potential 
M1 
CD cases 
M0/Controls M1/CD M1/Controls 
χ2 p χ2 p χ2 p 
c-REL 
(rs842647) 
AA 
404 
(56.8%) 
26 
(47.3%) 
33 
(47.8%) 
359 
(56.4%) 
2.91 0.23 11.98 <0.01 10.9 <0.01 AG 
272 
(38.3%) 
24 
(43.6%) 
26 
(37.7%) 
249 
(39.1%) 
GG 
35 
(4.9%) 
5 
(9.1%) 
10 
(14.5%) 
29 
(4.6%) 
            
CCR 
(rs6441961) 
AA 
99 
(13.9%) 
11 
(23.4%) 
9 
(15.8%) 
120 
(18.8%) 
6.12 0.04 1.20 0.55 4.22 0.12 AG 
318 
(44.7%) 
24 
(51.1%) 
30 
(52.6%) 
293 
(46.0%) 
GG 
294 
(41.4%) 
12 
(25.5%) 
18 
(31.6%) 
224 
(35.2%) 
            
LPP 
(rs1464510) 
AA 
108 
(15.2%) 
12 
(21.8%) 
15 
(21.7%) 
152 
(23.9%) 
2.10 0.35 1.35 0.51 5.88 0.05 AC 
362 
(50.9%) 
28 
(50.9%) 
40 
(58.0%) 
324 
(50.9%) 
CC 
241 
(33.9%) 
15 
(27.3%) 
14 
(20.3%) 
161 
(25.3%) 
Table 11. Comparison between cases with completely normal mucosa (M0) and those 
with infiltrated mucosa (M1). 
 
The eleven cases which developed small intestinal atrophy during follow 
up did not show an allelic and genotypic distribution different from those 
who remained potential, maybe because of the sample size that was too 
small to evaluate differences. 
 
 Five Candidate SNPs on the 4q genomic region 
The 4q27 region, among non-HLA genes, is the one resulted to be 
associated with CD in all GWAs and replications performed until now.  
Despite the limited sample size we found that three SNPs in the 4q 
genomic region showed significant differences between controls and 
potential CD patients (rs4374642, rs13119723 and rs6840978) in their 
genotype distribution. In addition, we found also significant differences 
between potential CD and CD patients for three SNPs (rs4374642, 
rs13119723 and rs6822844) (Table 12). 
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  Controls 
Potential 
CD 
χ
2
 
p 
value 
CD cases 
Potential 
CD 
χ
2
 
p 
value 
KIAA1109 
(rs4374642) 
CC   
4.52 0.03 
4 
(1.2%) 
 
7.22 0.03 CT 
63 
(14.2%) 
9 (7.1%) 
53 
(15.3%) 
9 
(7.1%) 
TT 
381 
(85.8%) 
118 
(92.9%) 
290 
(83.6%) 
118 
(92.9%) 
          
KIAA1109 
(rs13119723) 
AA 
397 
(88.6%) 
104 
(81.3%) 
5.99 0.05 
290 
(84.1%) 
104 
(81.3%) 
8.16 0.02 AG 
48 
(10.7%) 
21 
(16.4%) 
55 
(15.9%) 
21 
(16.4%) 
GG 
3 
(0.7%) 
3 
(2.3%) 
 
3 
(2.3%) 
          
KIAA1109 
(rs1127348) 
CC 
16 
(3.6%) 
8 
(6.3%) 
2.05 0.36 
9 
(2.6%) 
8 
(6.3%) 
3.51 0.17 CT 
122 
(27.5%) 
37 
(29.1%) 
103 
(30.3%) 
37 
(29.1%) 
TT 
205 
(68.8%) 
82 
(64.6%) 
228 
(67.1%) 
82 
(64.6%) 
          
IL2/IL21 
(rs6822844) 
GG 
358 
(80.1%) 
103 
(79.8%) 
0.35 0.84 
267 
(81.9%) 
103 
(79.8%) 
7.61 0.02 GT 
82 
(18.3%) 
23 
(17.8%) 
59 
(18.1%) 
23 
(17.8%) 
TT 
7 
(1.6%) 
3 
(2.3%) 
 
3 
(2.3%) 
          
IL21 
(rs6840978) 
CC 
363 
(81.6%) 
85 
(72.0%) 
17.94 <0.01 
222 
(76.8%) 
85 
(72.0%) 
4.5 0.10 CT 
82 
(18.4%) 
29 
(24.6%) 
65 
(22.5%) 
29 
(24.6%) 
TT  
4 
(3.4%) 
2 
(0.7%) 
4 
(3.4%) 
Table 12. Association results for 5 celiac non-HLA risk variants, located on 4q27 locus. 
 
Although rs1127348 and rs6840978 produced an interesting difference 
between CD cases and Potential CD (in term of χ2 which is 3.51 and 4.5 
respectively), they could not reach the statistical significance (Table 12). 
 
The rs4374642, rs13119723 and rs6840978 SNPs, respectively, were 
significantly associated when Potential CD cases were compared to 
Controls. In contrast, only the rs4374642*T was the risk allele associated 
with potential cases when compared to CD cases (Table 13). 
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Potential CD and Controls 
SNP Locus A1  A2  
Pot CD 
Cases,  
Controls 
Ratios 
MAF 
Pot CD 
cases 
MAF 
Controls 
χ
2
 
p 
value 
Odds ratio 
(95% confidence 
interval) 
rs4374642 KIAA1109 T C 
249:9, 
823:63 
0.03 0.07 4.44 0.03 2.12 (1.04-4.32) 
rs13119723 KIAA1109 A G 
229:27, 
832:54 
0.10 0.06 5.97 0.01 0.55 (0.34-0.89) 
rs1127348 KIAA1109 T C 
201:53, 
732:154 
0.21 0.17 1.61 0.20 0.80 (0.56-1.13) 
rs6822844 IL2/IL21 G T 
228:28, 
796:96 
0.11 0.10 0.01 0.94 0.98 (0.63-1.53) 
rs6840978 IL21 C T 
199:37, 
802:82 
0.16 0.09 8.04 <0.01 0.55 (0.36-0.83) 
Potential CD and CD patients 
SNP Locus A1  A2  
Pot CD 
Cases,  
CD cases 
Ratios 
MAF 
Pot CD 
cases 
MAF 
CD 
cases 
χ
2
 
p 
value 
Odds ratio 
(95% confidence 
interval) 
rs4374642 KIAA1109 T C 
249:9, 
622:58 
0.03 0.08 7.17 0.01 2.58 (1.26-5.29) 
rs13119723 KIAA1109 A G 
229:27, 
604:54 
0.10 0.08 1.25 0.26 0.76 (0.47-1.23) 
rs1127348 KIAA1109 T C 
201:53, 
552:120 
0.21 0.18 1.10 0.29 0.82 (0.58-1.18) 
rs6822844 IL2/IL21 G T 
228:28, 
592:58 
0.11 0.09 0.87 0.35 0.79 (0.49-1.28) 
rs6840978 IL21 C T 
199:37, 
503:69 
0.16 0.12 1.92 0.17 0.74 (0.48-1.14) 
Table 13. Association results of non-HLA SNPs Alleles, located on chromosome 4q27.  
 
Cases which developed small intestinal atrophy during follow up did not 
show an allelic (Table 14) and genotypic (data not shown) distribution 
different from those which remained potentials. 
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Potential CD which develop villous atrophy and still Potential CD cases 
SNP Locus A1 A2 
Pot CD with 
atrophy, 
Still Pot Ratios 
MAF 
Pot CD 
with 
atrophy 
MAF 
Still 
Potential 
CD  
χ2 
p 
value 
Odds ratio 
(95% confidence 
interval) 
rs2816316 RGS1 A C 16:6, 195:37 0.27 0.15 1.83 0.17 0.51 (0.18-1.38) 
rs917997 IL18RAP G A 18:4, 172:60 0.18 0.25 0.63 0.43 1.57 (0.51-4.82) 
rs1464510 LPP A C 12:10, 114:118 0.45 0.49 0.23 0.63 1.24 (0.52-2.99) 
rs2327832 OLIG3 A G 14:8, 191:39 0.36 0.16 4.98 0.02 0.36 (0.14-0.91) 
rs1738074 TAGAP G A 13:9, 128:104 0.40 0.44 0.12 0.72 1.17 (0.48-2.85) 
rs842647 c-REL A G 15:7, 159:73 0.31 0.31 0.01 0.97 0.98 (0.38-2.52) 
rs6441961 CCR G A 14:8, 124:108 0.36 0.46 0.84 0.36 1.52 (0.61-3.78) 
rs17810546 SCHIP1 A G 20:2, 207:25 0.09 0.10 0.06 0.80 1.21 (0.27-5.48) 
rs4374642 KIAA1109 T C 22:0, 219:9 0.00 0.03 0.90 0.34 1.95 (1.10-34.61) 
rs13119723 KIAA1109 A G 21:1, 204:26 0.04 0.11 0.96 0.33 2.67 (0.34-20.74) 
rs1127348 KIAA1109 T C 18:4, 179:49 0.18 0.21 0.13 0.72 1.23 (0.40-3.81) 
rs6822844 IL2/IL21 G T 21:1, 204:26 0.04 0.11 0.96 0.33 2.68 (0.34-20.74) 
rs6840978 IL21 C T 14:2, 182:34 0.12 0.14 0.12 0.73 1.31 (0.28-6.02) 
Table 14. Association results of 13 non-HLA SNPs alleles. 
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Discussion 
This work attempts to explore the genetic profiles of potential Celiac 
patients, characterized by a positive serology and undamaged small 
intestinal mucosa: they appear to be associated to different genetic risk 
factors compared with CD patients and controls.  
Potential CD have a HLA-related CD risk significantly lighter than that of 
CD cases; no difference in HLA profile was observed between M0 and M1 
potential patients, neither between the cases who developed full blow 
disease and those who remained potential after a three years follow-up. 
It’s important to note that potential patients without the classical DQ2 or 
DQ8 heterodimers (HLA risk group 5) were double in potential (18.0%) 
than in classical celiacs (9.0%), but they produced antibodies against 
Human anti-tTG, with positive Endomysial antibodies, in some cases as 
much as CD cases with proper DQ2.5 heterodimer. In addition we could 
find no discrimination on the outcome between the DQ2/DQ8 carriers and 
those who carried only half of the heterodimers.  
We identified six polymorphisms suggestive to be differently distributed 
between controls and potential CD: in particular those in KIAA1109, IL-21, 
LPP, c-REL and CCR genes. We suppose that these factors are implicated at 
some stages of CD pathogenesis, and that, as for HLA, there may be a 
“gene-dosage effect”. 
We are interested especially in c-REL gene, a subunit of the NF-B 
complex, crucial for the regulation of this major nuclear factor for the 
innate and adaptive immunity. Our group produced consistent evidence of 
the very early involvement of NF-B mechanism in the gliadin-induced 
innate immune response in CD (Maiuri et al., 2003): NF-B is constitutively 
active in intestinal mucosa of patients with untreated CD and reverts to 
normal values when gluten is removed from the diet. On these basis we 
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think that sustained activation of NF-B in intestinal mucosa of CD patients 
leads to prolonged induction of inflammatory genes expression and 
thereby perpetuates the chronic inflammatory process. 
Potential patients have most of the features of CD patients: they have 
similar genes, produce the same antibodies but they lack the final 
destructive phase of the gluten induced immunoresponse, the cytotoxic 
destruction of small intestinal mucosa. No clinical, serological or 
histological features could distinguish M0 from M1 patients up to now 
(Tosco et al., 2011), for the first time we can speculate that potential CD 
are a mixture of two populations, with different non-HLA genetics and 
significant differential expression of some candidate genes. 
Those potential cases who developed full blow mucosal damage on 
follow up, did not show any of the time 0 serologic markers worse than 
those who remained potential over a prolonged follow up. Similarly no 
genetic polymorphism, including HLA, could predict the outcome of these 
potential cases. We observed the same distribution of the HLA as well as of 
the non-HLA genes in the cases who eventually become full blown celiacs. 
The limit of this study is the relatively short follow up time of this 
cohort: up to now it was not possible to identify any marker (clinical, 
environmental, serological or genetic) that could help to predict the time 
of conversion from predisposition to the disease. In conclusion we cannot 
state that the cohort of potential celiacs who have again shown an 
undamaged intestinal mucosa after 4 to 6 years of follow up, will not 
eventually develop it later in life. We can only observe that this group did 
not developed the full blown disease after 4-6 years. But the genetic and 
expression features point to the existence of a peculiar molecular profile, 
that may help to identify cases who do not have the complete molecular 
repertoire to develop the disease. They may indeed be considered a live 
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biological model of CD pathogenesis, where the process is, for some time 
or even forever, interrupted just before the final destructive phase. 
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Chapter 3. Non-HLA genes and Celiac Disease: A Family study 
Background and aim 
Since several studies showed an elevated prevalence of Celiac Disease 
(CD) in sibs of CD patients, our group previously evaluated the CD risk in 
sibs of CD patients (Bourgey et al., 2007). The study included a cohort of 
188 Italian families, composed by CD probands, at least one sib and both 
parents and permitted to classify people in five different group of risk 
according to HLA genotype (Table 8). 
The evidence of a strong genetic component is suggested by a 
remarkable familiar aggregation: the prevalence of CD is, in fact, 10 times 
higher in first degree relatives (~10%) than in the whole population (1%) 
(Bonamico et al., 2006; Bourgey et al., 2007; Mustalahti et al., 2010) and a 
very high concordance (>80%) is found in monozygotic twins (Greco et al., 
2002). 
In the field of complex diseases, particularly in CD, great attention is 
now paid to use the available genetic data to predict the risk of disease in 
asymptomatic individuals and to support the diagnosis in ambiguous cases. 
Although it was described that non-HLA genes improve the ability to 
identify individuals at high risk the increased prediction ability by genetics 
only seems still modest in the general population (Romanos et al., 2009). 
However the use of non-HLA genes in the disease risk prediction in CD sibs 
has not yet been fully explored. 
 The aim of this study was to develop a genetic risk model for CD using 
HLA and non-HLA risk alleles. For this study, we analysed families 
previously recruited (Bourgey et al., 2007) to evaluate the CD risk in sibs of 
children with CD. In fact, the study includes a cohort of 188 Italian families, 
composed by a CD proband, at least one sib and both parents. Preliminary 
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data show that at least one non-HLA risk allele increases the risk of CD. 
This effect can be added in an additive model to HLA risk.  
We aim to significantly improve the identification of subjects at risk to 
develop CD by modeling the HLA risk with the newly discovered genetic 
profile in order to improve the accuracy in prediction. When this goal is 
reached, families with one case will know, with reliable accuracy, the 
individual risk of a newborn and will be able to anticipate the onset of the 
clinical phenotype by a simple point-of-care tests. After families the model 
might well be extended to populations, in the frame of national policies to 
screen for genetic predispositions to diseases. 
 
Methods 
Family Samples 
A cohort of CD families was recruited  in a previous study (Bourgey et 
al., 2007). Families included a symptomatic CD patient (hereafter referred 
as the proband), both parents and at least one sib with known outcome 
(for a total of 183 probands, 366 parents and 249 sibs); all probands, as 
well as the new cases, were diagnosed according to the European Society 
of Paediatrics Gastroenterology and Nutrition (ESPGHAN) criteria (Husby 
et al., 2012). Among the 249 sibs, 33 resulted to be affected over a 6 years 
follow up program. 
All individuals were grouped into five decreasing risk classes according 
to their HLA genotype: very high (>20% with two copies of DQ2.5, or 
DQ2.5/DQ2.2 Group 1), high (15–20% with DQ2.2/DQA105, Group 2), 
intermediate (10–15% with one copy of the DQ2.5 heterodimer, Group 3), 
moderate (1–10% with a double copy of DQ8 or DQ2.2/DQ8, or double 
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copy of DQ2.2, Group 4) or negligible (<1%, with other genotype, Group 5) 
(Table 8). 
The informed consent was obtained from all participants and from both 
parents for children. The research was approved by the Ethics Committee 
of the School of Medicine, University of Naples “Federico II” and was 
according to principles of the Helsinki II declaration. 
 
Non-HLA Single Nucleotide Polymorphisms (SNPs) typing 
The 798 patients were genotyped for 10 non-HLA SNPs associated with 
CD: rs6441961 on 3p21 (CCR1/CCR3), rs17810546 and rs9811792 on 3q25-
26 (IL12A/SCHIP1 and IL12A), rs1738074 on 6q25 (TAGAP – T cell 
activation GTPase activating protein), rs2816316 on 1q31 (RGS1 – 
Regulator of G-protein signaling 1), rs1464510 on 3q28 (LPP – Lipoma 
Preferred Partner), rs2327832 on 6q23.3 (OLIG3), rs842647 on 2p16.1 
(REL), rs6822844 on 4q27 (IL2/IL21), rs3184504 on 12q24 (SH2B3). 
Genotyping reactions were performed using TaqMan®SNP Genotyping 
Assays on a 7900HT Fast Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA); the final volume was 5 µL, containing master mix, 
TaqMan assays and about 60 ng of genomic DNA template. All 384 well 
plates were filled using Biomek® FX (Beckman Coulter, Indianapolis, IN, 
USA). Allelic Discrimination results were analyzed through the SDS 
software ver. 2.3. 
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Analysis strategy and statistics 
In order to develop the model we splitted the sample into a training and 
a testing set. In the training set, composed by probands and their 
unaffected parents, called trios, we evaluated which SNP was associated 
with the disease, independently from the HLA haplotype. Twenty-six CD 
families were excluded because they did not meet the requirements for 
the analysis (e.g. there was an affected parent or patients had an 
incomplete genotyping), so the training set was composed by 157 trios 
(Figure 12).  
 
Figure 12. Study design: the family set was splitted in a Testing set – 157 trios 
composed by the 157 probands and their unaffected parents – and a Training set – 252 
sibs of the probands. 
 
As control haplotypes we considered the haplotypes carried by parents 
and not transmitted to the affected probands, as they could be 
representative of the haplotypes in the general population, from which 
cases are originated. The frequencies of HLA and non HLA haplotypes in 
controls were estimated by the AFBAC (Affected Family Based Controls) 
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method implemented in the MASC software tool (Thomson, 1995).To 
evaluate the association of the SNPs with the disease, we performed a 
Transmission Disequilibrium Test (TDT) by using the trio package ver. 
1.1.15 for R statistical computing software ver 2.11.2. This method is based 
on multivariate logistic regression. We considered: dominant, the 
heterozygote genotype when it had the same risk effect of the high risk 
homozygote genotype; recessive, the heterozygote genotype when it had 
the same risk effect of the low risk homozygote genotype; additive, the 
heterozygote genotype when it had a risk effect intermediate between the 
two homozygote genotypes. Firstly, we evaluated the monovariate 
association between each SNP and the disease. Secondly, among those 
resulted to be significantly associated with CD, we evaluated the SNP-SNP 
interactions by the logistic regression model. Finally, the interaction 
between significant SNPs and HLA groups was verified by an interaction 
test. 
To evaluate the joint effect of HLA and SNPs to influence the risk to 
develop CD in sibs, we applied a Bayesian approach, focusing only on those 
SNPs resulted significantly associated with CD at TDT analysis. Usually 
Bayes' revision of probabilities allows the computation of an individual 
probability of an event given the a priori data from the general population 
where the patient comes from. We arbitrarily selected an a priori 
probability of 0.5, because in our situation we could not apply the Bayes’ 
revision of probabilities and obtain an a posteriori risk of CD in sibs. Indeed 
the estimated 10% of CD risk in first grade relatives also account for the 
role of genetics, therefore it cannot be used as an a priori probability to 
calculate the a posteriori probability, after considering the risk conferred 
by genetic factors (SNPs).  
Firstly we considered the different frequencies of HLA genotypes in 
probands and controls and secondly the non-HLA SNPs genotypes 
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frequencies. According to the Bayesian approach, in each run we used the 
score obtained in the previous step as the new a priori value for the 
following step. By this approach, it was possible to assign to HLA only or to 
each combination of HLA plus LPP, RGS1 and REL SNPs genotypes a 
Bayesian Score (BS). Secondly, we assigned to each sib (testing set) a BS in 
dependence of the specific HLA-SNPs genotype combination found. We 
arbitrarely established the median BS as discrimination threshold between 
low and high risk sibs and evaluated how affected and unaffected sibs 
were distributed.  
 
Results  
SNPs evaluation and computation of the Bayesian Score 
All individuals were typed for 10 CD associated SNPs (Dubois et al., 
2010) and the TDT test was performed on results obtained from 157 trios 
of the training set (Figure 12). Three out of ten investigated SNPs 
(rs1464510 in LPP, rs842647 in REL and rs2816316 in RGS1 genes) were 
significantly associated with CD (Table 8). In particular: rs1464510 in LPP 
gene showed a strong association (p<0.001) according to an additive 
model, whereas, both rs2816316 in RGS1 and rs842647 in REL genes were 
also significantly associated (respectively p=0.025 and p=0.034), by a 
recessive model (Table 15). 
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SNP Gene Model 
Risk 
Allele 
OR (95% CI) p value 
rs1464510 LPP Additive A 2.36 (1.64-3.41) <0.001 
rs2816316 RGS1 Recessive A 1.75 (1.07-2.86) 0.025 
rs842647 REL Recessive A 1.66 (1.04-2.65) 0.034 
rs2327832 OLIG3 Additive G 1.35 (0.90-2.03) 0.150 
rs6441961 CCR1/CCR3 Additive A 1.24 (0.89-1.72) 0.189 
rs6822844 IL2/IL21 Additive C 1.43 (0.82-2.49) 0.210 
rs1738074 TAGAP Dominant A 1.31 (0.79-2.16) 0.293 
rs3184504 SH2B3 Additive A 1.19 (0.86-1.63) 0.294 
rs17810546 IL12A Additive G 1.10 (0.80-1.51) 0.572 
rs9811792 IL12A/SCHIP1 Dominant G 1.10 (0.59-2.05) 0.753 
Table 15. Genotypic Transmission Disequilibrium Test (TDT) results. 
 
The other seven investigated SNPs, even if not statistically associated 
with CD, showed always an higher frequency of the previously reported 
risk alleles (Dubois et al., 2010) in affected subjects than in controls. 
  
Training set 
  
Probands Parents 
LPP 
A* 0.52 0.43 
C 0.48 0.57 
OLIG3 
A 0.76 0.79 
G* 0.24 0.21 
RGS1 
A* 0.88 0.85 
C 0.12 0.15 
REL 
A* 0.77 0.75 
G 0.23 0.25 
SH2B3 
A* 0.55 0.53 
G 0.45 0.47 
CCR 
A* 0.41 0.39 
G 0.59 0.61 
IL2/IL21 
A 0.09 0.11 
C* 0.91 0.89 
IL12A 
A 0.57 0.58 
G* 0.43 0.42 
TAGAP 
A* 0.42 0.41 
G 0.58 0.59 
SCHIP1 
A 0.92 0.93 
G* 0.08 0.07 
Table 16. allelic frequencies observed in Training set (Trios). *Associated allele.  
 
In order to evaluate the occurrence of HLA-SNP interaction, we 
stratified the training set (Figure 9) according to the HLA risk group of the 
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proband. No statistically significant interaction was found between HLA 
and non-HLA genes (data not shown). 
To compute the Bayesian Score (BS) we compared the frequency of 
each HLA+SNPs genotype combination detected in probands and in 
controls (Training set, Figure 9). Through this approach we obtained a BS 
for each HLA+SNPs genotype combination (data not shown).  
 
Validation of the BS and testing of a classification model 
The validation set (Figure 12) was composed by the sibs of the 
probands, both affected (n=29) and unaffected (n=220). In these subjects 
we evaluated if HLA+SNPs genotyping could improve the identification of 
CD risk in sibs better than HLA only.  
We assigned to each sib, both affected and unaffected, the BS value 
corresponding to his HLA+SNPs genotype combination as previously 
calculated in the training set (Table 17).  
Associated SNPs BS 
LPP 
(rs1464510) 
REL 
(rs842647) 
RGS1 
(rs2816316) 
HLA 
Group 
1 
HLA 
Group 
2 
HLA 
Group 
3 
HLA 
Group 
4 
HLA 
Group 
5 
CC AG|GG AC|CC 0.66 0.63 0.32 0.30 0.04 
CC AG|GG AA 0.74 0.73 0.42 0.39 0.06 
CC AA AC|CC 0.71 0.69 0.38 0.35 0.05 
CC AA AA 0.79 0.77 0.48 0.46 0.08 
AC AG|GG AC|CC 0.81 0.80 0.52 0.49 0.09 
AC AG|GG AA 0.87 0.86 0.62 0.60 0.13 
AC AA AC|CC 0.85 0.84 0.58 0.55 0.11 
AC AA AA 0.90 0.89 0.68 0.66 0.16 
AA AG|GG AC|CC 0.91 0.90 * 0.69 0.18 
AA AG|GG AA 0.94 0.93 0.79 0.77 0.25 
AA AA AC|CC 0.93 0.92 0.76 0.74 0.22 
AA AA AA 0.95 0.95 0.83 0.81 0.30 
Table 17. Bayesian Score (BS) assigned to each HLA-SNPs genotype combination. 
*The combination LPP*AA - REL*AG|GG - RGS1*AC|CC for HLA group 3 was not found 
among our sibs’ cohort. 
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We observed an increase of average BS values from HLA group 5 to HLA 
group 1 and, within all 5 HLA groups we found an increase of the BS 
corresponding to an increase of “A” alleles in the haplotype combination. 
In order to identify sibs at high risk to develop CD, we distributed affected 
and unaffected sibs on the basis of their BS (under or above median BS) 
within each HLA group from G1 to G5 (Figure 13).  
 
Figure 13. Distribution of CD sibs based on their BS. Affected (n=29) and unaffected 
(n=220) CD sibs were classified on the basis of their BS value < or ≥ median BS within 
each HLA group. Horizontal lines correspond to the median BS of all sibs in each HLA 
risk-group (HLA Group 1 = 0.90, HLA Group 2 = 0.86, HLA Group 3 = 0.62, HLA Group 4 = 
0.60, HLA Group 5 = 0.13). 
 
Considering the distribution of all the sibs, it is evident that above the 
median BS within each HLA group, there was always a larger number of 
affected sibs than under the median: 72% (21/29) versus 28% (8/29). 
Interestingly, 2/29 affected sibs that being at lower HLA risk (HLA group 4 
and 5) could be misclassified, were correctly classified by their BS above 
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the median. We calculated the Odds Ratio (OR) of CD classification based 
on the BS, above or under the median, within each HLA group. CD sibs with 
a BS value above the median, had more than two fold higher risk (OR) 
compared to CD sibs with a BS value under the median (2.53, 95% C.I.: 
1.68-3.39; p=0.047).  
In our previous work, we estimated the HLA related risk to develop CD, 
defining a risk range from 0.01 to 0.21 (Bourgey et al, 2007). To refine the 
previous HLA based estimation of risk by this new approach we set the HLA 
related mean risk as the a priori risk of the Bayesian Model. Having set the 
HLA risk at the median level of the Bayesian Score, we produced a picture 
of the variation of risk given by the non-HLA genes for each HLA class 
(Figure 14).  
 
Figure 14. Refining the CD risk estimate. The picture shows the modification of the a 
priori HLA related risk by the number of the at risk “A” alleles of the LPP, REL and RGS1 
SNPs. From top to bottom lines correspond to HLA group 1 to 5. 
 
It is remarkable that the addition of the 3 SNPs does modify the HLA 
only risk through the 5 HLA risk classes, also in subjects with no DQ2 
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neither DQ8 haplotype, where the increase in risk is significantly larger 
than that observed in HLA risk classes. 
The addition of only 3 SNPs to the HLA significantly improved the 
prediction of CD risk in sibs, identifying, within a specific HLA group, those 
individuals which are more likely to become celiacs. In fact, considering 
HLA 1 and 2 as the highest risk groups (Bourgey et al., 2007), we calculated 
the diagnostic characteristics of our proposed HLA+SNPs genotype 
combination obtaining both an higher predictive negative value (NPV) and 
an higher diagnostic sensitivity (DS) than HLA only, respectively 95% vs 
91% (NPV) and 79% vs 45% (DS) (Table 18). 
 
 HLA risk groups 1-2 HLA-SNPs genotype combination 
Sensitivity 0.45 (0.27-0.64) 0.79 (0.73-0.84) 
Specificity 0.71 (0.65-0.77) 0.54 (0.48-0.60) 
NPV 0.91 (0.87-0.96) 0.95 (0.92-0.98) 
PPV 0.17 (0.12-0.22) 0.19 (0.14-0.24) 
Table 18. diagnostic characteristics of HLA  and HLA-SNPs genotype combination. 
 
Although the discovery of 39 polymorphism associated to CD improved 
the estimation of the heritability of only 4-5% (Dubois et al., 2010), in this 
Bayesian  model the addition of only three SNPs of associated genes 
improves the sensitivity of risk prediction  of 34% compared to the HLA 
only model.  
The computation of the AUC of the ROC curve output a C statistic equal 
to 0.70 for HLA and 0.73 for HLA+SNPs classifications, showing that the 
inclusion of SNPs moderately improved the prediction ability. 
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Discussion 
In our previous work, we considered in CD families the risk to develop 
the disease according to a specific HLA haplotypes, obtaining a risk range 
from 0.01 to > 0.20 (Bourgey et al., 2007). In the present study we 
evaluated the role of 3 non-HLA genetic markers to influence the CD risk in 
first relatives of CD affected children.  
We collected data on families with at least one CD-affected offspring. 
This family set helped to evaluate the association between SNPs and CD 
(TDT on parents-offspring trios) and to estimate the risk of CD in the other 
sibs. The TDT design provides robustness to population stratification and 
mitigation of the possible confounding effect of environmental factors, 
because all family members share the same environment (Schaid, 1996).  
Ten SNPs, selected from those previously found to be associated with 
CD by GWAS (Dubois et al., 2010), were successfully genotyped. In our 
population three SNPs resulted significantly associated with CD (those in 
LPP, RGS1 and REL genes) and the other seven investigated SNPs, even if 
not statistically associated with CD, showed always an higher frequency of 
the previously reported risk alleles in affected subjects than in controls. 
The three genes selected appear to be appealing for the pathogenesis 
of CD. LPP (OR=2.36; p<0.001) was reported to be highly expressed in 
small intestinal mucosa and may have a structural role at sites of cell 
adhesion in maintaining cell shape and motility (Hunt et al., 2008). RGS1 
(OR=1.75; p=0.025) belongs to a family of RGS genes. It attenuates the 
signaling activity of G-proteins, blocking the homing of Intra Epithelial 
Lymphocytes (IELs), and it is specifically expressed both in human small 
intestinal mucosa and in murine IELs, key players in the development of 
human CD villous atrophy (Hunt et al., 2008; Pennington et al., 2003). REL 
(OR=1.66; p=0.034) is a subunit of NF-B complex, implicated in T cell 
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differentiation (Son et al., 2011) and it appears to be a key molecule 
regulating inflammation and the switch from tolerance to autoimmunity 
(Liou & Smith, 2011). It is interesting to note that our data confirm 
previous pathogenic implications reported in the literature of these SNPs 
with CD as well as with other autoimmune diseases (Abadie et al., 2011).  
By the Bayesian approach we calculated a ranking score (BS) among the 
sibs. However, it should be considered that BS is not a plain disease risk, 
rather a method to rank different genotypes according to their 
contribution to individual susceptibility to CD. For instance, some of our BS 
are very near to 1, nevertheless none of the considered genotypes could 
give a 100% risk to develop the disease. In other terms, we considered the 
BS as a ranking measure, only stating that a given genotype could assign a 
higher risk than another genotype but does not allow a quantitative 
measure of the risk difference (2-fold, 3-fold, etc). However, even if the 
addition of only 3 SNPs to HLA could be considered at “minor effect”, we 
demonstrated that they could significantly improve the prediction of CD 
risk in sibs, in terms of diagnostic sensitivity and negative predictive value. 
So, in a cohort of CD families, our data confirm that non-HLA SNPs 
evaluation is an useful diagnostic tool in CD risk evaluation as a previous 
study showed in CD unrelated subjects (Romanos et al., 2009). 
CD, on the basis of the actual knowledge, cannot be exactly predicted 
by genetic testing, but a reliable probabilistic method might be associated 
to careful surveillance of infants carrying the higher risk. This will help to 
significantly reduce the heavy load of anxiety and pain associated with the 
appearance of symptoms of CD, by anticipating, with simple serological 
tests, the clinical appearance of the disease.  
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To improve the possibility to identify high risk patients in CD families we 
propose in alternative to the classical HLA classification (Figure 11) a slight 
improved flow-chart (Figure 12). 
 
Figure 11. Classification flow-chart. The classical HLA-based classification.  
 
Figure 12. The proposed BS-based classification considering the genotypes of HLA 
plus LPP, RGS1 and REL SNPs. 
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1) HLA genotyping: subjects belonging to the HLA risk groups 1 and 2 
will be classified as at high CD risk;  
2) subjects belonging to the HLA risk groups 3 and 4, will be further 
investigated for our SNPs combination (LPP, REL, RGS1) in order to 
calculate their BS (Figure 12). Among these latter subjects those 
with a BS > the median value will be classified at high risk;  
3) subjects belonging to the HLA risk group 5 will be considered at low 
CD risk. All CD familiars belonging to the above high risk groups 
(HLA group 1-2 and HLA group 3-4 with BS > median) will be 
undergo a strict surveillance.  
One of the limitation of our family study could be the sample size, which 
may have not allowed to explore genes at smaller effect, so explaining the 
lack of association between SNPs in TAGAP, IL2/IL21, OLIG3, CCR, SH2B3, 
IL12A and IL12A/SCHIP1 genes with CD although the trend observed in 
previous studies in unrelated CD patients was confirmed (Dubois et al., 
2010). In the main time the homogeneity of the genetic and environmental 
domains in the tested families allows to explore risk factors within a 
controlled cohort. A second limit of the study is the relatively short (6 
years) follow up of the sibship, which could cause an underestimation of 
the disease development at later ages. Our aim is to go on with the 
monitoring of these families in the next years.  
In conclusion, the estimate of the CD risk by HLA+SNPs approach, even 
if not applicable to prevention, could be a precious tool improving CD 
diagnosis respect to the only HLA (NPV: 95% vs 91%, and DS: 79% vs 45%), 
in the cohort of first degree relatives. In fact in clinical practice the 
absence of HLA risk groups 1 or 2, allows to exclude the disease with high 
probability, while testing the three SNPs in HLA groups 3 or 4 could 
represent a further tool to identify less frequent CD cases. So, an infant 
with high HLA+SNPs score even if belonging to HLA low risk groups, shall 
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undergo a simple surveillance system to allow proper diagnosis and 
treatment before the full blow disease appearing. 
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General conclusions and perspective 
Our aim is to extract as many information as we can from the large 
amount of data emerged from GWAs. Even though some research groups 
are investing on this issue, the discovery of new associated genes does not 
prove any pathogenic mechanism behind the development of CD. In fact 
the rationale for GWAS is the ‘common disease, common variant’, where 
common variant are those present in more than 5% of the population 
(Manolio et al., 2009). For this reason, SNP chips or array cannot evaluate 
deletion and duplication (carried by 8% of the general population) and 
copy-number variation (CNV) inaccessible by most existing genotyping and 
sequencing technologies. Furthermore Gene-Environment (GxE) or Gene-
Gene (GxG) interactions (Hindorff et al., 2009; Manolio et al., 2009), not to 
mention the possible epigenetic and regulation (microRNA) effects (Eichler 
et al., 2010; Slatkin, 2009), cannot be revealed by GWAS and despite their 
ability to detect the role of genetic factors in complex diseases, literature 
about this issue is still poor. Next generation sequencing technologies 
could be performed in extreme phenotypes in order to identify other 
associated variants, both common and rare. But again, the accumulation of 
data from GWAs and from others investigation methods will lead, on the 
long run, to consider genes associated to CD genes encoding proteins 
involved in immunity and inflammation, describing the physiological cell 
functions, without bringing new substantial data to rewrite the 
pathogenesis of the disease.  
It would be more appropriate to focus only on some of them, to be sure 
that "making a list of genes" wasn’t seen in an un-useful way. During my 
PhD training, my group and I tried to speculate in a critical way around the 
non-HLA genes issue. For this reason my PhD thesis project is articulated at 
various points.  
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Firstly, we tried to improve the analyses of candidate genes analyzing 
their expression profile and comparing the results obtained on mucosal 
biopsies, peripheral monocytes and T-cell lines isolated from duodenal 
mucosa: three different cell population with three different functions and 
locations, in order to give a picture of the variation in the celiac type and 
to correlate it with a model of CD pathogenesis. In this way we were able 
to localize the role of these genes in one area rather than another. After 
that, stimulated by the recently proposed discriminant analysis of celiac 
gene expression as a promising diagnostic tool with which to distinguish 
celiac mucosa from normal mucosa (Bragde et al.,2011), we evaluated the 
diagnostic strength of this analysis on the gene expression data obtained 
from peripheral blood monocytes. Our final aim was to  provide a less 
invasive alternative to duodenal biopsy as the only diagnostic tool for CD. 
Using a discriminant analysis, we demonstrate that the expression of a 
small set of candidate genes in peripheral blood monocytes can be used to 
correctly classify CD patients from controls and from patients affected by 
Crohn disease, without considering HLA and anti-tTG levels, because 
otherwise the diagnostic power of our method could has been hidden by 
the  very high sensitivity and specificity of the former and the very high 
negative predictive value of the latter.  
Speaking in an over-optimistically way, this should be done in clinical 
practice in order to increase the sensitivity and the specificity of the 
diagnosis when duodenal biopsy is not available. 
Secondly, we aimed to investigate the non-HLA genetics of Potential CD 
patients. The term ‘potential CD’ was assigned to individuals with proper 
DQ2 or DQ8, production of anti-tTG, normal small intestinal mucosa, 
classified as Marsh 0 (no damage) or Marsh 1 stage (unspecific intra 
epithelial infiltration only). These are also defined “serological positive 
cases” (O. Koskinen et al., 2008; Kurppa et al., 2010). Potential patients 
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suggest that the development of adaptive anti-gluten immunity is not 
sufficient to develop villous atrophy. This is supported by animal models 
showing that inflammatory anti-gluten responses are not sufficient to 
develop mucosal lesions. Thus, we can subgroup individuals into three 
groups: controls, patients who developed antibodies but no intestinal 
lesions (M0 and M1 potentials) and patients with antibodies and villous 
atrophy (overt CD). Analyzing differences among these subgroups may 
shed light into the genes differentially involved in development of adaptive 
anti-gluten immunity (different between control and potential) and tissue 
lesions (different between potential and CD), as well as genes involved in 
all steps of CD pathogenesis (different between control and potential, and 
potential and CD). 
Potential patients have most of the features of CD patients: they have 
similar genes, produce the same antibodies but they lack the final 
destructive phase of the gluten induced immunoresponse, the cytotoxic 
destruction of small intestinal mucosa. No clinical, serological or 
histological features could distinguish M0 from M1 patients up to now 
(Tosco et al., 2011). For the first time we can speculate that potential CD 
are a mixture of two populations, with different non-HLA genetics and 
significant differential expression of some candidate genes. 
 
Thirdly, we tried to use the new genetic findings in order to build a risk 
model for CD using HLA and non-HLA risk alleles and to significantly 
improve the identification of subjects at risk to develop CD. We developed 
a classification system based on a score (Bayesian Score) which can be 
easily calculated on the basis of three family-associated genes (LPP, c-REL 
and RGS1) and that permits to discriminate between patients at higher or 
lower risk to develop the disease. In this way, families with one affected 
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case will know, with reliable accuracy, the individual risk of a newborn and 
will be able to anticipate the onset of clinical phenotype by a simple point-
of-care tests. 
In conclusion, the critic analysis of the large panorama of CD candidate 
genes leads to consider several mechanisms of action that may have gone 
unnoticed if we persist in considering all the genes together. Whereas, 
analyzing a small set of genes from different points of view it is possible to 
really understand why this or that gene has resulted to be associated with 
the disease.  
GWAs made the history of complex diseases, but represent only the 
starting point from which postulate hypothesis, mechanisms of action, 
interactions, in order to untangle the skein represented by the complex 
pathogenesis of celiac disease. 
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